

Antimicrobial peptides from *Phyllomedusa* frogs: from biomolecular diversity to potential nanotechnologic medical applications

Leonardo de Azevedo Calderon · Alexandre de Almeida E. Silva ·
Pietro Ciancaglini · Rodrigo Guerino Stábéli

Received: 3 February 2010 / Accepted: 5 May 2010
© Springer-Verlag 2010

Abstract Screening for new bioactive peptides in South American anurans has been pioneered in frogs of the genus *Phyllomedusa*. All frogs of this genus have venomous skin secretions, i.e., a complex mixture of bioactive peptides against potential predators and pathogens that presumably evolved in a scenario of predator–prey interaction and defense against microbial invasion. For every new anuran species studied new peptides are found, with homologies to hormones, neurotransmitters, antimicrobials, and several other peptides with unknown biological activity. From Vittorio Ersamer findings, this genus has been reported as a “treasure store” of bioactive peptides, and several groups

focus their research on these species. From 1966 to 2009, more than 200 peptide sequences from different *Phyllomedusa* species were deposited in UniProt and other databases. During the last decade, the emergence of high-throughput molecular technologies involving de novo peptide sequencing via tandem mass spectrometry, cDNA cloning, pharmacological screening, and surface plasmon resonance applied to peptide discovery, led to fast structural data acquisition and the generation of peptide molecular libraries. Research groups on bioactive peptides in Brazil using these new technologies, accounted for the exponential increase of new molecules described in the last decade, much higher than in any previous decades. Recently, these secretions were also reported as a rich source of multiple antimicrobial peptides effective against multidrug resistant strains of bacteria, fungi, protozoa, and virus, providing instructive lessons for the development of new and more efficient nanotechnological-based therapies for infectious diseases treatment. Therefore, novel drugs arising from the identification and analysis of bioactive peptides from South American anuran biodiversity have a promising future role on nanobiotechnology.

L. A. Calderon · R. G. Stábéli (✉)
Centro de Estudos de Biomoléculas Aplicadas a Medicina
“Professor Dr. José Roberto Giglio” (CEBio), Núcleo de Saúde
(NUSAU), Universidade Federal de Rondônia (UNIR),
Porto Velho, RO 76800-000, Brazil
e-mail: stabeli@fiocruz.br

L. A. Calderon · A. A. E. Silva
Instituto de Pesquisas em Patologias Tropicais de Rondônia
(IPEPATRO), Porto Velho, RO 76812-245, Brazil

A. A. E. Silva
Laboratório de Bioecologia de Insetos, Departamento de
Biologia, Núcleo de Ciência e Tecnologia (NCT),
Universidade Federal de Rondônia (UNIR),
Porto Velho, RO 76800-000, Brazil

P. Ciancaglini
Departamento de Química da Faculdade de Filosofia, Ciências e
Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo
(USP), Ribeirão Preto, SP 14040-901, Brazil

R. G. Stábéli
Fundação Oswaldo Cruz do Noroeste do Brasil,
Fundação Oswaldo Cruz, Porto Velho, RO, Brazil

Keywords *Phyllomedusa* · Bioprospection ·
Antimicrobial peptide · Dermaseptin · Infection disease ·
New drugs · Nanobiotechnology

Abbreviations

ADR	Adenoregulin
AFM	Atomic force microscopy
AMP	Antimicrobial peptide
CD	Circular dichroism
DRP	Dermaseptin related peptide
DRS	Dermaseptin

DRT	Dermatoxin
FSAP	Frog skin active peptide
FTIR	Fourier-transformed infrared spectroscopy
HIV-1	Human immunodeficiency virus 1
HSV-1	Herpes simplex virus 1
MALDI	Matrix assisted laser desorption ionization
NMR	Nuclear magnetic resonance
NPY	Neuropeptide Y
PLS	Phylloseptin
PLX	Phylloxin
PM	Plasmatic membrane
PTC	Plasticin
PYY	Polypeptide YY
SPYY	Skin polypeptide YY
UniProt	Universal protein resource

South America Phyllomedusae biodiversity

According to Frost, up to now, over 5,600 anuran species have been described around the world, in a wide variety of environments, except in the poles (Frost 2009). Compared to other continents, South America includes the highest number of the anuran species of the world in its biomes (Toledo and Jared 1995). Brazil (821 spp.) (SBH 2009), Colombia (732 spp.) (Frost 2009), and Ecuador (480 spp.) (Coloma 2009) are the richest countries in anurans' species in South America.

Among all South American anurans, a complex group of 32 valid species of *Phyllomedusa* frogs (Table 1) deserve special attention. The *Phyllomedusa* genus belongs to the subfamily Phyllomedusinae (Amphibia, Anura, Hylidae) that has seven genera of neotropical tree frogs distributed from Central America to the east Andes along South America (*Agalychnis*, *Cruziohyla*, *Hylomantis*, *Pachymedusa*, *Phasmahyla*, *Phrynomedusa*, and *Phyllomedusa*). The *Phyllomedusa* species display unique characters among the neotropical hylidae, including vertical slit pupil, green back, hidden regions with contrasting patterns of red, blue, and yellow (Caramaschi 2006). Eggs deposited out of water give rise to aquatic larvae with different exclusive characters, in addition to 95 transformations in nuclear and mitochondrial proteins and ribosomal genes (Faivovich et al. 2005).

According to Caramaschi (2006), most of the *Phyllomedusa* species are distributed among five groups: *P. burmeisteri* group, *P. hypochondrialis* group, *P. buckleyi* group, *P. perinesos* group, and *P. tarsius* group (Caramaschi 2006). There are, however, some species that are currently not assigned to any group, such as *P. atelopoides*, *P. bicolor*, *P. coelestis*, *P. palliata*, *P. tomopterna*, *P. trinitatis*, *P. vaillantii*, and *P. venusta* (Caramaschi 2006).

The species belonging to the *Phyllomedusa* genus are frequently renamed by herpetologists. These changes influence other science areas that depend on the correct taxonomic identification, mainly the “omics” sciences, such as proteomics, peptidomics, secretomics, genomics, and others, leading to new molecules described in discontinued, invalid, or non-described species names.

The *Phyllomedusa* cutaneous glands

The anuran skin displays great morphofunctional diversity adapted to a number of adverse factors present in the species habitat environment (Toledo and Jared 1993; Barra and Simmaco 1995). The cutaneous glands present in the skin play an essential role in respiration, reproduction, defense against predators and protection against desiccation, and proliferation of microorganisms on the body surface (Toledo and Jared 1995). Ultrastructural characterization of the *Phyllomedusa* species skin demonstrated that the profile of skin glands are composed by three types of cutaneous glands (acinous) differed in size and secretory activity. These are lipid, mucous, and serous glands that lie deep in the skin and subcutaneous connective tissue (Lacombe et al. 2000).

The lipid glands promote the impermeabilization of the skin in order to decrease water loss (Castanho and De Luca 2001). The mucous glands produce mucus to support cutaneous functions, such as respiration, reproduction, thermoregulation, and defense (Toledo and Jared 1995). The serous glands are the largest and are widely distributed over the animal's body surface, as a main element in amphibian passive defense (Toledo and Jared 1995; Lacombe et al. 2000). These glands produce a wide variety of noxious or toxic substances with various pharmacological effects on microorganisms, vertebrate, and invertebrate species (Toledo and Jared 1995; Lacombe et al. 2000). The serous glands exhibit remarkable polymorphism in *Phyllomedusa* (Delfino et al. 1998). They are classified basically into two classes, type I and II (Lacombe et al. 2000).

Type I glands exhibit a poorly developed smooth endoplasmic reticulum (Lacombe et al. 2000) and present two subtypes, Ia and Ib. Type Ia shows dense granules which characterize the biosynthesis of proteinaceous products reserved for exocytosis, and engage both rough endoplasmic reticulum and Golgi apparatus (Delfino 1991). Type Ib shows vesicles holding a lucent material in the fluid serous secretions on the anuran skin, which undergo maturation without condensation (Toledo and Jared 1995).

Type II glands, typical of *Phyllomedusa bicolor*, show a well-developed smooth endoplasmic reticulum that is possibly engaged in the biosynthesis of peptides (Blaylock et al. 1976; Lacombe et al. 2000). These peptides are

Table 1 Up to date list of *Phyllomedusa* species distributed by group and number of peptides characterized

Group	Species	Number of peptides	References
<i>P. burmeisteri</i> [5 species]	<i>P. bahiana</i>	—	
	<i>P. burmeisteri</i>	29	Barra et al. (1994), Mandel (2008), Mundim (2008), UniProt (2009)
	<i>P. distincta</i>	6	Batista et al. (1999, 2001)
	<i>P. iheringii</i>	—	
	<i>P. tetraploidea</i>	—	
<i>P. hypochondrialis</i> [11 species]	<i>P. araguari</i>	—	
	<i>P. azurea</i>	41	Thompson (2006), Thompson et al. (2006), Thompson et al. (2007a, b), UniProt (2009)
	<i>P. ayeaye</i>	—	
	<i>P. centralis</i>	—	
	<i>P. hypochondrialis</i>	34	Leite et al. (2005), Brand et al. (2006a, b), Chen et al. (2006), Conceição et al. (2006, 2007), UniProt (2009)
	<i>P. itacolomi</i>	—	
	<i>P. megacephala</i>	—	
	<i>P. nordestina</i>	3	Conceição et al. (2009)
	<i>P. oreades</i>	6	Brand et al. (2002), Leite et al. (2005)
	<i>P. palliata</i>	—	
<i>P. rohdei</i>	22	Anastasi et al. (1966), Barra et al. (1985), Montecucchi et al. (1986), Mandel (2008), Mundim (2008)	
<i>P. perinesos</i> [4 species]	<i>P. baltea</i>	—	
	<i>P. duellmani</i>	—	
	<i>P. ecuatoriana</i>	—	
	<i>P. perinesos</i>	—	
<i>P. tarsiis</i> [5 species]	<i>P. boliviana</i>	—	
	<i>P. camba</i>	—	
	<i>P. neildi</i>	—	
	<i>P. sauvagii</i>	31	Anastasi et al. (1969), Montecucchi et al. (1979), Montecucchi et al. (1981a), Montecucchi et al. (1981b), Erspamer et al. (1985), Richter et al. (1987), Mor et al. (1991a, b), Chen et al. (2003a, b), Mor and Nicolas (1994a), Chen and Shaw (2003), Chen et al. (2005a), UniProt (2009)
	<i>P. tarsiis</i>	12	Silva et al. (2000), UniProt (2009)
Unassigned to group [7 species]	<i>P. atelopoides</i>	—	
	<i>P. bicolor</i>	21	Anastasi et al. (1970), Richter et al. (1990), Daly et al. (1992), Mignogna et al. 1992, Amiche et al. (1993), Amiche et al. (1994), Mor et al. (1994a, b); Charpentier et al. (1998); Fleury et al. (1998), Seon et al. (2000), Amiche et al. (2000), Pierre et al. (2000), Vanhoye et al. (2003), Chen et al. (2005b), UniProt (2009)
	<i>P. coelestis</i>	—	
	<i>P. tomopterna</i>	21	Mandel (2008), Mundim (2008), UniProt (2009)
	<i>P. trinitatis</i>	1	Marenah et al. (2004)
	<i>P. vaillantii</i>	—	
	<i>P. venusta</i>	—	

synthesized as prepropeptides that are processed into mature peptides after removal of the peptide signal and the acidic propiece. These are then stored in the granules (Nicolas and El Amri 2009). It is proposed that the release

of the gland content onto the skin surface is mediated by a holocrine mechanism involving rupture of the plasmatic membrane (PM) and extrusion of the granules through a duct opening to the surface (Nicolas and El Amri 2009).

Immunofluorescence analysis of the *P. bicolor* dermal glands using an antibody to the acidic propeptide region of the preprodermaseptin/preprodeltorphins-derived family [ENENEENHEEGSE] demonstrated that the fluorescence-positive reaction is restricted to the serous glandular content, indicating their specificity in the biosynthesis and secretion of dermaseptins and deltorphin peptides (Lacombe et al. 2000). A recent mass spectral image study (MALDI-image) of the skin of *P. hypochondrialis* indicates that the serous glands present specialization in the peptide production and storage (Brand et al. 2006b).

Peptides of *Phyllomedusa* skin secretions

In spite of the large number of anuran species from different genera found within South America, a great deal of attention is being paid to the study of neotropical hyloid frogs that belong to the subfamily *Phyllomedusinae*, as an excellent source of these molecules. Erspamer et al. (1985) also stated that “No other amphibian skin can compete with that of the *Phyllomedusae*”. The initial efforts on *Phyllomedusa* skin secretions by Vittorio Erspamer followed by other scientists around the world during the last four decades revealed a complex cocktail of biologically active peptides with antimicrobial, hormonal, and neuro activities (Bevins and Zasloff 1990; Amiche et al. 1993). The peptides secreted differ significantly among species within this genus leading to an interesting molecular diversity, associated with possible specific differences present in the specie niche, such as the interactions with environment, predators, and pathogens characterizing *Phyllomedusa* species evolution.

The first peptide isolated from the *Phyllomedusa* skin was Phyllokinin [RPPGFSPFRIY], a bradykinyl-isoleucyl-tyrosine *O*-sulfate from *P. rohdei* in 1966 (Anastasi et al. 1966), followed by Phyllocaerulein [QEYTGWMDF-NH₂] a cerulein-like nonapeptide from *P. sauvagii* in 1969 (Anastasi et al. 1969). All these bioactive peptides were discovered by Erspamer’s research group. Due to technical limitations, large numbers of specimens have to be killed in order to isolate, characterize, and perform the biological assays on the two peptides. Since the 1960s, the number of *Phyllomedusa* peptides discovered has increased exponentially (Fig. 1, inset) followed by the drastic reduction of specimens required for the analyses. Nowadays, it is possible to carry out transcriptome analysis to build a cDNA library only with the secretions from a single living specimen (Chen et al. 2003b). The impacts caused by the bio-prospecting activity on the frog natural populations tend to zero through the development of non-invasive techniques largely due to scientific and technical advances.

The emergence of modern high-throughput molecular technologies involving de novo peptide sequencing via




Fig. 1 *Phyllomedusa* peptides and prepropeptides amino acid sequences published on indexed scientific journals including the structures deposited in genomic and proteomic databases from 1965 to 2009. Inset number of *Phyllomedusa* primary structures increment per year showing an exponential growth

tandem mass spectrometry, cDNA cloning, and pharmacological screening applied to peptide discovery allowed fast structural data analysis and the generation of peptide sequence libraries, which in turn increased the capacity of peptide characterization, remarkably reducing the amount of samples needed (Shaw 2009).

The chronology related to the analyses of the *Phyllomedusa* peptide discovery (Fig. 1) was impacted by the technological evolution applied to the study of venom-derived peptides, including the emergence of new research groups dedicated to the characterization of anuran venoms.

From 1966 to 2009, 227 peptide amino acid sequences, including peptide precursor cDNA sequences, belonging to the frog skin active peptide (FSAP) family from the skin of *Phyllomedusa* species (Fig. 1, inset) were published in scientific papers and/or deposited on genomic and/or proteomic data banks as the Universal Protein Resource Consortium (UniProt). The species *P. azurea*, *P. bicolor*, *P. burmeisteri*, *P. distincta*, *P. hypochondrialis*, *P. nordestina*, *P. oreades*, *P. rohdei*, *P. sauvagii*, *P. tarsius*, *P. tomopterna*, and *P. trinitatis* that belong to all groups, except the *P. perinesos* group, had their secreted peptides sequenced by 2009 (Table 1).

The *Phyllomedusa* skin peptides are grouped in to three main groups according to their “primary” activity: antimicrobial peptides (AMPs); smooth muscle active peptides; and nervous system active peptides (Table 2) (Erspamer et al. 1981). However, peptides’ secondary activities were not considered in this systematization. The

Table 2 Skin peptide families, main activity, and distribution on *Phyllomedusa* species

Main activity	Peptide family	Species											
		<i>P. azurea</i>	<i>P. bicolor</i>	<i>P. burmeisteri</i>	<i>P. distincta</i>	<i>P. hypochondrials</i>	<i>P. nordestina</i>	<i>P. oreades</i>	<i>P. rohdei</i>	<i>P. sauvaigi</i>	<i>P. tarsius</i>	<i>P. tomopterna</i>	<i>P. trinitatis</i>
Antimicrobial	<i>Dermaseptin</i> (Mor et al. 1991a)	X	X	X	X	X	X	X	X	X	X	X	X
	<i>Dermatoxin</i> (Amiche et al. 2000)	X							X	X			
	<i>Distinctin</i> (Batista et al. 2001)	X		X	X								
	<i>Phylloseptin</i> (Lete et al. 2005)	X	X	X		X	X	X		X	X	X	
	<i>Phylloxin</i> (Pierre et al. 2000)	X								X			
	<i>Plasticins</i> (Vanhoeye et al. 2004)	X								X			
	<i>SPYY</i> (Mor et al. 1994a, b)	X								X			
	<i>Deltorphin</i> (Erspamer et al. 1989)	X								X			
	<i>Dermorphin</i> (Broccardo et al. 1981)	X				X			X	X			
	<i>Bradykinin</i> (Brand et al. 2006a)	X		X			X		X	X			X
	<i>Phyllokinin</i> (Anastasi et al. 1966)	X				X			X	X			
	<i>Tryptophyllin</i> (Gozzini et al. 1985)	X				X			X	X			
<i>Litorin</i> (Barra et al. 1985)								X					
<i>Phyllolitorin</i> (Yasuhara et al. 1983)										X			
<i>Phyllomedusin</i> (Anastasi and Erspamer 1970)		X											
<i>Phyllocaerulein</i> (Anastasi et al. 1969)										X			
<i>Sauvagine</i> (Montecucchi et al. 1980)										X			
<i>Sauvatide</i> (Wang et al. 2009)										X			
<i>S-Calcitonin</i> gene related (Seon et al. 2000)		X											
Unknown	<i>Hyposin</i> (Thompson et al. 2007b)											X	

first group acts as a skin anti-infective passive defense barrier, the second and the third groups cause the disruption of the predator homeostasis balance. The biological activity of the hyposin peptides is still unknown.

Antimicrobial peptides

Among the peptides of the FSAP family, the AMPs are the most diverse class. To date, the AMPs described in *Phyllomedusa* skin include seven distinct families (or subfamilies) according to their sequence similarity and activity, e.g., *Dermaseptin* (Mor et al. 1991a), *Dermatoxin* (Amiche et al. 2000), *Distinctin* (Batista et al. 2001), *Phylloseptin* (Leite et al. 2005), *Phylloxin* (Pierre et al. 2000), *Plasticin* (Vanhoye et al. 2004), and *Skin Polypeptide YY* (Mor et al. 1994a, b, c). These peptides comprise the skin anti-infective passive defense barrier of these anurans. According to Pierre et al. (2000), the biological significance of such a complex mixture of antibiotic peptides with different specificity and potency in *Phyllomedusa* skin is possibly related to a greater protection against a wide range of potential invaders at a minimum metabolic cost (Pierre et al. 2000), e.g., dermaseptins exhibit synergy of action upon combination with other antibiotic molecules or AMPs, resulting in a 100-fold increase in antibiotic activity potency (Mor and Nicolas 1994b; Giacometti et al. 2006).

These peptides differ in amino acid composition, length, structure, specificity, and several other non-antimicrobial activities, but share common physico-chemical properties, such as cationic charge and an amphipathic structure when interacting with PMs. They have also shared a conserved prepro region originating from a single gene family named preprodermorphin/dermaseptins-derived peptides family that unites them (Nicolas and El Amri 2009). This canonical precursor (Table 3) has an architecture that comprises: a N-terminal pre-sequence composed by the signal peptide, with the first 22 amino acid residues; the acidic propiece with 21–24 residues in the middle region, that terminates in a typical -KR- propeptide convertase processing motif that cleaves and releases each respective mature peptide located at the C-terminus (Chen et al. 2005a) with remarkably conserved, both within and between species; and a markedly different C-terminal domain sequence corresponding to chemically and functionally different mature peptides with 19–34 residues that include amphipathic antimicrobial peptides as well as dermorphins and deltorphins, D-amino acid-containing heptapeptides which are very potent and specific agonists of the μ -opioid or δ -opioid receptors (Erspamer 1992; Amiche et al. 1998, 1999; Lazarus et al. 1999; Pierre et al. 2000; Nicolas et al. 2003; Vanhoye et al. 2003; Nicolas and El Amri 2009).

Despite the intensive studies, the complete and precise structure–activity relationships and mechanisms of the AMPs action are still not fully understood (Nicolas and El Amri 2009). Morphological and functional assays confirm that PM permeabilization is achieved by distortion of the PM structure, not by activation of a pre-existing pore or transporter (Rivas et al. 2009). The ensuing effects depend on the antimicrobial peptide and the severity of the damage, and usually include dissipation of ionic gradients across the PM, leakage of nutrients and/or larger cytoplasmic components, and finally, a collapse of the parasite bioenergetics and osmotic lysis. This killing mechanism acts promptly by destroying their PM, promoting the reduction of log orders of pathogens in a few minutes (Feder et al. 2000). This mechanism is unlikely to induce antibiotic-resistance in microorganisms due to a great metabolic change in the PM composition (Shai 1995).

Two elements seem to be relevant to the antimicrobial action: the selectiveness, and the ability to destabilize PMs (Hwang and Vogel 1998; Dathe and Wieprecht 1999; Shai 2002; Yeaman and Yount 2003). The biochemical and biophysical properties of the peptide, e.g., amphipathicity, charge, conformation, hydrophobicity, and polar angle, result from the interrelationship between the physico-chemical properties of the amino acid composition and its position in the sequence, driving the peptide three-dimensional configuration (Yeaman and Yount 2003). Therefore, changes in composition, sequence, and intramolecular bonds may profoundly affect the structure–activity relationships of the solubilized AMPs, upon binding to target PMs. The coordination of these events allow the optimization of antimicrobial peptide efficacy determined by the balance between increased affinity against a microbial target versus reduced toxicity to host cells (Matsuzaki 2009).

Matsuzaki (2009) stated that strong antimicrobial activity and less cytotoxicity could be achieved by increasing the net positive charge of the peptide with minimal hydrophobicity above a threshold, which is supported by the hypothesis that the lipid composition of cell surfaces primarily determines cell selectivity. The hydrophobicity responsible for cytotoxicity is displayed by the hydrophobic face of the amphipathic secondary structure formed upon binding to the PM. Residues close to the ends of a helix do not fully contribute to the effective hydrophobicity (Matsuzaki 2009).

According to Nicolas and El Amri (2009), the peptide antimicrobial potency is essentially independent of the bacterial envelope structure, related to the AMP selectiveness. Ultrastructural studies performed by electron microscopy and immunocytochemistry (Hernandez et al. 1992) and also biophysical studies with liposomal models (Pouny et al. 1992) demonstrated that dermaseptin exerts its action through selective lysis of PMs (Mor and Nicolas

Table 3 Primary structures of *Phyllomedusa* antimicrobial prepropeptides

Name ^a	Abbreviation ^a	Prepropeptide Sequence ^b	Species	Digital abstract
Dermaseptin	AZ3	DRS-AZ3 (DMSS3)		Q17UY8 (http://www.uniprot.org/uniprot/Q17UY8.html)
	AZ4	DRS-AZ4 (DMSS4)		Q1E1P4 (http://www.uniprot.org/uniprot/Q1E1P4.html)
	AZ5	DRS-AZ5 (DMSS5)		Q1E1P5 (http://www.uniprot.org/uniprot/Q1E1P5.html)
	B1	DRS-B1		P80282 (http://www.uniprot.org/uniprot/P80282.html)
	B2	DRS-B2 (ADR)		P31107 (http://www.uniprot.org/uniprot/P31107.html)
	B3	DRS-B3		P81485 (http://www.uniprot.org/uniprot/P81485.html)
	B4	DRS-B4		P81486 (http://www.uniprot.org/uniprot/P81486.html)
	B6	DRS-B6		P81490 (http://www.uniprot.org/uniprot/P81490.html)
	B7	DRS-B7 (DRG1)		Q90ZK3 (http://www.uniprot.org/uniprot/Q90ZK3.html)
	B8	DRS-B8 (DRG2)		Q90ZK5 (http://www.uniprot.org/uniprot/Q90ZK5.html)
B9	DRS-B9 (DRG3)		P81488 (http://www.uniprot.org/uniprot/P81488.html)	
H1	DRS-H1 (DSHypo 01)		P84596 (http://www.uniprot.org/uniprot/P84596.html)	
H2	DRS-H2 (DSN-1)		Q0VZ37 (http://www.uniprot.org/uniprot/Q0VZ37.html)	
S1	DRS-S1 (DS1)		Q7T3K6 (http://www.uniprot.org/uniprot/Q7T3K6.html)	
S6	DRS-S6 (SVI)		Q7T3K9 (http://www.uniprot.org/uniprot/Q7T3K9.html)	
S7	DRS-S7 (SVII)		Q7T3K8 (http://www.uniprot.org/uniprot/Q7T3K8.html)	
S8	DRS-S8 (SVIII)		Q7T3K7 (http://www.uniprot.org/uniprot/Q7T3K7.html)	
S9	DRS-S9 (DSS9)		Q1EN15 (http://www.uniprot.org/uniprot/Q1EN15.html)	
S11	DRS-S11 (DS11)		Q1EN13 (http://www.uniprot.org/uniprot/Q1EN13.html)	
S12	DRS-S12 (DS12)		Q1EN12 (http://www.uniprot.org/uniprot/Q1EN12.html)	
S13	DRS-S13 (DS13)		Q1EN11 (http://www.uniprot.org/uniprot/Q1EN11.html)	
Dermatoxin	DRT-B1		Q9PT75 (http://www.uniprot.org/uniprot/Q9PT75.html)	
S1	DRT-S1		Q5DYA5 (http://www.uniprot.org/uniprot/Q5DYA5.html)	
Phylloseptin	AZ1	PLS-AZ1 (PS-2)		P85881 (http://www.uniprot.org/uniprot/P85881.html)
	AZ2	PLS-AZ2 (PS-7)		P85882 (http://www.uniprot.org/uniprot/P85882.html)
	AZ3	PLS-AZ3 (PS-8)		P85883 (http://www.uniprot.org/uniprot/P85883.html)
	AZ4	PLS-AZ4 (PS-12)		Q17UY9 (http://www.uniprot.org/uniprot/Q17UY9.html)
	AZ7	PLS-AZ7 (PS-15)		Q0VKG9 (http://www.uniprot.org/uniprot/Q0VKG9.html)
	B1	PLS-B1 (PBN1)		Q800R3 (http://www.uniprot.org/uniprot/Q800R3.html)
	H2	PLS-H2 (PS-2)		P84567 (http://www.uniprot.org/uniprot/P84567.html)
H5	PLS-H5 (PS-7)		P84572 (http://www.uniprot.org/uniprot/P84572.html)	
H6	PLS-H6 (PS-8)		Q0VZ41 (http://www.uniprot.org/uniprot/Q0VZ41.html)	
H7	PLS-H7 (PS-9)		Q0VZ38 (http://www.uniprot.org/uniprot/Q0VZ38.html)	
H8	PLS-H8 (PS-10)		Q0VZ39 (http://www.uniprot.org/uniprot/Q0VZ39.html)	
H9	PLS-H9 (PS-11)		Q0VZ40 (http://www.uniprot.org/uniprot/Q0VZ40.html)	
Phylloxin	B1	PLX-B1		P81565 (http://www.uniprot.org/uniprot/P81565.html)
	S1	PLX-S1		Q5DYA6 (http://www.uniprot.org/uniprot/Q5DYA6.html)
Plastacin	B1	PLC-B1 (PBN2)		Q800R4 (http://www.uniprot.org/uniprot/Q800R4.html)
	S1	PLC-S1 (DS10)		Q1EN14 (http://www.uniprot.org/uniprot/Q1EN14.html)

^a The peptides are named according to the nomenclature proposed by Amiche et al. (2008), the original nomenclature are in brackets

^b The prepropeptide comprises a signal peptide (bold font) followed by an acidic propeptide (normal font) that ends in a typical prohormone processing signal -KR- (italic bold font) that precedes the single downstream copy of the antimicrobial peptide progenitor sequence (italic font)

1994b). Furthermore, biophysical investigations indicate that the PM surface charge helps with the association of cationic peptides, but does not affect the channel structures themselves (Béven et al. 1999; Bechinger 2004; Gregory et al. 2008). Recent investigations by isothermal titration calorimetry (ITC) and by fluorescence spectroscopy support that the addition of cholesterol to phosphatidylcholine mimetic PMs lead to a decrease of dermaseptin membrane interactions and the concomitant disruption of the lipid bilayers (Verly et al. 2008). Other investigations through atomic force microscopy (AFM) indicated that dermaseptin is able to disrupt anionic PMs typical of bacteria (Silva et al. 2008). Fluorescence spectroscopy studies with liposomes and surface plasmonic resonance (SPR) analysis of the interaction of dermaseptins with immobilized bilayers demonstrated that the peptides preferentially bind to negatively charged membranes (Verly et al. 2009). Theoretical predictions and circular-dichroism (CD) studies indicated that dermaseptin is highly propense to fold into a cationic and amphipathic helix in hydrophobic medium, a structure indicative of PM lysing potential (Mor and Nicolas 1994a, b; Shalev et al. 2002; Lequin et al. 2003; Castiglione-Morelli et al. 2005). According to Verly et al. (2009), the unstabilization induced by the insertion of the peptide in one bilayer of the PM propagates from one bilayer to the next, triggering the loss of lipid order as a function of PM thickness (Verly et al. 2009). This effect is most pronounced on peptides that mismatch the bilayer thickness or those oriented parallel to the membrane surface (Harzer and Bechinger 2000).

The main advanced models for PM permeation by amphipathic helical peptides are very different, e.g., a canonical trans PM pore (barrel-stave); solubilization of the PM by a detergent-like action (Bechinger 2005) based on the amphipathic character of the AMPs and their massive accumulation into the PM (carpet model); and an intermediate two-state model (worm-hole) (Matsuzaki 1998; Papo and Shai 2003; Huang et al. 2004; Bechinger and Lohner 2006; Chan et al. 2006). The first two models are limited experimentally, e.g., the prediction that the PM permeation occurs at very low peptide:phospholipid ratio, assuming that peptide–peptide interaction is stronger than the peptide–phospholipid in the barrel-stave model, or the need for the whole covering of the organism by the peptide in the carpet model (Huang et al. 2004). The intermediate worm-hole or two-state model proposed independently by Matsuzaki and Huang (Matsuzaki 1998) tries to integrate three experimental observations: (1) the change in orientation undergone by a fraction of PM bound peptide once a threshold is reached, (2) peptide-induced phospholipid flip-flop, and (3) peptide translocation into the cytoplasm, ignored by the carpet and barrel-stave model (Rivas et al. 2009).

In this model, the massive union of the AMPs into the external monolayer of the PM leads to its expansion, causing a mechanical stress. Once a threshold is reached, a fraction of the peptides lying parallel to the plane of the PM, change their orientation from parallel to transversal, promoting a positive curvature of the PM and forming a mixed phospholipid–peptide toroidal pore, where the hydrophobic lining is provided both by the polar heads of the phospholipids and the hydrophilic face of the peptides. This pore also acts as catalyst in the phospholipid interchange between the two leaflets. This pore is transitory and, when it disappears, stochastically sends it's forming monomers to either side of the PM (Rivas et al. 2009). This more comprehensive model is a subtle tour de force refinement over the detergent carpet-like model and supports the step-wise increase in conductivity observed for several AMPs (Rivas et al. 2009).

Two other models are also proposed; a fourth mechanism, the “aggregate model” (Chan et al. 2006), relaxes the structural requirements intrinsic to the toroidal model, mostly applicable to α -helical peptides, to accommodate peptides not adopting this prototypical cylindrical shape (Rivas et al. 2009) and a fifth model, the so called “Droste mechanism” (Sengupta et al. 2008), indicating that the toroidal lumen adopts a poor orientation and the hydrophilic lining is mostly provided by the positive curvature of the phospholipids, with a scarce role of the peptide, which accumulates at the rim of the pore and stabilizes it (Rivas et al. 2009).

Dermaseptin

The dermaseptin family comprises a large class of PM damaging polycationic (K-rich) peptides with different lengths (28–34 residues) and amino acid sequences that undergo coil-to-helix transition upon binding to lipid bilayers (Nicolas and El Amri 2009) found in the skin of *Phyllomedusa azurea*, *P. bicolor*, *P. burmeisteri*, *P. distincta*, *P. hypochondrialis*, *P. oreades*, *P. rohdei*, *P. sauvagii*, *P. tarsius*, *P. tomopterna*, and *P. trinitatis* (see Table 2). Generally, they all have conserved a W residue at position 3 usually preceded by AL- or GL-, an AG[A]K[Q]A[M]A[V]L[G]G[N/K]A[F]V[A/L] consensus motif in the middle or C-terminal region and positive charge due to the presence of K residues that punctuate an alternating hydrophobic and hydrophilic sequence (Table 4).

The first dermaseptin described was a 34-amino acid antimicrobial peptide termed dermaseptin-S1 identified in skin extract of *P. sauvagii* (Mor et al. 1991a). This peptide has lytic activity against Gram-positive and Gram-negative bacteria, yeast, and protozoa, but does not damage mammalian cells. This was the first gene-encoded eukaryotic peptide with lethal effect against filamentous fungi

responsible for opportunistic infections in immunodeficiency syndrome or immunosuppressed individuals (Nicolas and El Amri 2009). This was followed by the isolation of adenoregulin (also named dermaseptin-B2) from *P. bicolor* skin, a peptide that interacts with the adenosine receptor (Daly et al. 1992), and dermaseptin-B1 (Mor et al. 1994a, c). These two peptides were thought to be unrelated, but the cloning of their precursor polypeptides revealed the existence of the canonical precursor (Amiche et al. 1993; Vouille et al. 1997). After that, additional members of the dermaseptin family were rapidly identified in various South American anuran species (Lequin et al. 2006; Nicolas and El Amri 2009).

Dermaseptins and their analogs have lytic activity in vitro against a broad spectrum of free-living microorganism strains of the wall-less bacteria: *Acholeplasma laidlawii*, *Spiroplasma apis*, *S. citri*, *S. floricola*, and *S. melliferum* (Fleury et al. 1998); Gram-negative bacteria: *Aeromonas caviae* (Mor and Nicolas 1994a, b; Strahilevitz et al. 1994), *Acholeplasma laidlawii* (Fleury et al. 1998), *Acetobacter calcoaceticus* (Brand et al. 2002), *Escherichia coli* (Mor and Nicolas 1994a, b; Strahilevitz et al. 1994; Fleury et al. 1998; Batista et al. 1999; Silva et al. 2000; Brand et al. 2002; Conceição et al. 2006; Brand et al. 2006b; Leite et al. 2008), *Neisseria gonorrhoeae* (Rydlo et al. 2006; Zairi et al. 2009), and *Pseudomonas aeruginosa* (Fleury et al. 1998; Batista et al. 1999; Silva et al. 2000; Brand et al. 2002, 2006b; Conceição et al. 2006; Leite et al. 2008); Gram-positive bacteria: *Corynebacterium glutamicum* (Fleury et al. 1998), *Enterococcus faecalis* (Batista et al. 1999; Silva et al. 2000), *Micrococcus luteus* (Conceição et al. 2006), *Nocardia* spp. (Leite et al. 2008), *Nocardia brasiliensis* (Mor and Nicolas 1994a, b; Strahilevitz et al. 1994), *Staphylococcus aureus* (Strahilevitz et al. 1994; Fleury et al. 1998; Batista et al. 1999; Silva et al. 2000; Brand et al. 2002, 2006b; Conceição et al., 2006; Leite et al. 2008), *Streptococcus dysgalactiae* (Leite et al. 2008), and *S. uberis* (Leite et al. 2008); the fungi: *Aspergillus fumigatus* (Mor and Nicolas 1994a, b), *Arthroderma simii*, *Cryptococcus neoformans* (Strahilevitz et al. 1994; Mor and Nicolas 1994a, b), *Candida albicans* (Mor and Nicolas 1994a, b; Strahilevitz et al. 1994; Leite et al. 2008; Zairi et al. 2008), *C. tropicalis*, *C. guilliermondii* (Leite et al. 2008), *Microsporium canis*, *Tricophyton rubrum* (Strahilevitz et al. 1994; Mor and Nicolas 1994a, b); Protozoa: *Leishmania major* (promastigotes) (Feder et al. 2000; Kustanovich et al. 2002; Gaidukov et al. 2003), *L. mexicana* (promastigotes) (Hernandez et al. 1992; Mor and Nicolas 1994b), *L. amazonensis* (epimastigotes and promastigotes) (Brand et al. 2006b), *L. chagasi* (promastigotes) (Zampa et al. 2009), *Plasmodium falciparum* (trophozoites) (Ghosh et al. 1997; Krugliak et al. 2000; Dagan et al. 2002), and *Trypanosoma cruzi* (trypomastigotes) (Brand et al. 2002); and Virus: HSV-1 (Belaid et al.

2002) and HIV-1 (Lorin et al. 2005; Zairi et al. 2009). The wall-less bacteria, *Mycoplasma gallisepticum* and *M. mycoides*, and Gram-negative bacteria, *Salmonella typhimurium*, are resistant to dermaseptin B9 (DRG3) from *P. bicolor* (Fleury et al. 1998).

Despite the sequence similarities, the dermaseptins differ in their action efficiency (Nicolas and El Amri 2009; Rivas et al. 2009). But they present rapid and irreversible antimicrobial effect and no toxic effects in mammalian cells in vitro (Kustanovich et al. 2002; Navon-Venezia et al. 2002). However, dermaseptin-S4 analogs had a potent activity against human sperm (Zairi et al. 2009).

Some of the peptides from the dermaseptin superfamily present other additional biological functions that have unclear relations with pathogen clearance, e.g., dermaseptin B2 (adenoregulin): isolated by Daly et al. (1992) as a peptide that stimulated the binding of agonists to A1 adenosine receptors and also enhanced the binding of agonists to several G-protein coupled receptors in rat brain PMs through a mechanism involving enhancement of guanyl nucleotide exchange at G-proteins (Shin et al. 1994); dermaseptin-B4: stimulates insulin release by acute incubation with glucose-responsive cells (Marenah et al. 2004); dermaseptin-S1: stimulates the production of reactive oxygen species and release of myeloperoxidase by polymorphonuclear leukocytes (Ammar et al. 1998).

Dermatoxin

Two dermatoxins were identified in the skin secretions of *Phyllomedusa bicolor*, *P. sauvagii*, and *P. tarsius*. The primary structures of dermatoxin are highly conserved exhibiting few chemically conservative amino acid substitutions (Chen et al. 2005a). In contrast to dermaseptins, dermatoxins do not have W in its composition, having instead a G residue at position 3, or an R residue preceded by AL- or SL- and followed by a conserved KGVG consensus sequence. From the middle of the C-terminus region, a high conserved sequence AT[G/S]VGKV[M/I]VA[S]IDQFG[D]KLLQ[E]A is observed (Table 5).

Another interesting feature was the presence of the C-terminal dipeptide -GQ on the *P. bicolor* dermatoxin-B1 (DRT-B1) (Amiche et al. 2000; Chen et al. 2005a). The dermatoxin is structured as a preproprotein of the dermaseptin family of peptide precursors (Table 3) and characterized by strongly conserved preproregions followed by C-terminal sequence domain of precursors of the dermaseptin family (Amiche et al. 2000).

Dermatoxin presents a cationic amphipathic α -helical conformation in low polarity media, which mimics the lipophilicity of the PM of target microorganisms (Amiche et al. 2000; Chen et al. 2005a). It is membranotropic and antimicrobial with a sequence and cell killing mechanism diverse from dermaseptin and phylloxin (Amiche et al.

Table 4 Primary structures of dermaseptins from *Phyllomedusa* species

Species	Dermaseptin	Abbreviation	Peptide	Digital abstract
<i>P. azurea</i>	AZ2	DRS-AZ2 (DMS2) ^a	GLWSKIKDVAAA AGKAALGAV NEALGEQ	P84937 (http://www.uniprot.org/uniprot/P84937.html)
	AZ3	DRS-AZ3 (DMS3) ^a	GLWSTIKNVAAA AGKAALGAL -NH ₂ ^b	Q17UY8 (http://www.uniprot.org/uniprot/Q17UY8.html)
	AZ4	DRS-AZ4 (DMS4) ^a	GLWSTIKNVGKEAAIA AGKAALGAL -NH ₂	Q1EJP4 (http://www.uniprot.org/uniprot/Q1EJP4.html)
	AZ5	DRS-AZ5 (DMS5) ^a	GLWSTIKNVGKEAAIA AGKAVLGS L-NH ₂	Q1EJP5 (http://www.uniprot.org/uniprot/Q1EJP5.html)
	AZ6	DRS-AZ6 (DMS6) ^a	GLWSTIKQKGKEAAIA AKAAGQAALGAL	P84936 (http://www.uniprot.org/uniprot/P84936.html)
	<i>P. bicolor</i>	B1	DRS-B1 (B1)	AMWKDVLKKIGTVALH AGKAALGAV ADTISQ-NH ₂ ^b
B2		DRS-B2 (B2)	GLWSKIKEVGEAAKA AKAAGKAALGAV SEAV-NH ₂ ^b	P31107 (http://www.uniprot.org/uniprot/P31107.html)
B3		DRS-B3 (B3)	ALWKNMLKGIGK LAGQAALGAV KTLVGAE	P81485 (http://www.uniprot.org/uniprot/P81485.html)
B4		DRS-B4 (B4)	ALWKDILKNVGA AKGAVLNTV TPDMVNQ-NH ₂	P81486 (http://www.uniprot.org/uniprot/P81486.html)
B5		DRS-B5 (B5)	GLWKNIKEAASKA AGKAALGFV NEMV	P81487 (http://www.uniprot.org/uniprot/P81487.html)
B6		DRS-B6 (B6)	ALWKDILKN AGKAALNE INQLVNQ-NH ₂	P81490 (http://www.uniprot.org/uniprot/P81490.html)
B7		DRS-B7 (DRG1)	GLWSNIKTAGKEAAKA AKGKAALGAV TDAV-NH ₂ ^b	Q90ZK3 (http://www.uniprot.org/uniprot/Q90ZK3.html)
B8		DRS-B8 (DRG2)	GLWSKIKEAGKAALTA AGKAALGAV SDAV-NH ₂ ^b	Q90ZK5 (http://www.uniprot.org/uniprot/Q90ZK5.html)
B9		DRS-B9 (DRG3)	ALWKTIIK AGKMI GS LAKN LLGSQAQPES	P81488 (http://www.uniprot.org/uniprot/P81488.html)
<i>P. burmeisteri</i>	BU1	DRS-BU1 (DS III-like)	ALWKNMLKGIGK LAGKAALGAV K	P86281 (http://www.uniprot.org/uniprot/P86281.html)
	BU2	DRS-BU2 (DRS-DI4-like)	ALWKNMLKGIGK LAGQAALGAV KTLVGA	P86279 (http://www.uniprot.org/uniprot/P86279.html)
	BU3	DRS-BU3 (DS VIII-like)	ALWKTMLKKLGTVALH AGKAALGAA ADTISQGA	P86280 (http://www.uniprot.org/uniprot/P86280.html)
<i>P. distincta</i>	DI1	DRS-DI1 (DD K)	GLWSKIKAAAGKEAAKAA AKGKAALNAV SEAV	P83638 (http://www.uniprot.org/uniprot/P83638.html)
	DI2	DRS-DI2 (DD L)	ALWKTLLKNVGA AKGKAALNAV TPDMVNQ	P83639 (http://www.uniprot.org/uniprot/P83639.html)
	DI3	DRS-DI3 (DD M)	ALWKTMLKKLGT MALHAGKAALGAA ADTISQ	P83640 (http://www.uniprot.org/uniprot/P83640.html)
	DI4	DRS-DI4 (DD Q1)	ALWKNMLKGIGK LAGQAALGAV KTLVGAE	P83641 (http://www.uniprot.org/uniprot/P83641.html)
	DI5	DRS-DI5 (DD Q2)	GLWSKIKE AAKTAG LMAGFVNDMV	P83642 (http://www.uniprot.org/uniprot/P83642.html)
<i>P. hypochondrialis</i>	H1	DRS-H1 (DSHypo 01) ^a	GLWSTIKNVGKEAAIA AGKAALGAL -NH ₂	P84596 (http://www.uniprot.org/uniprot/P84596.html)
	H2	DRS-H2 (DSHypo 02) ^a	GLWKSLLKNVGA AKGKAALNAV TPDMVNQ	P84597 (http://www.uniprot.org/uniprot/P84597.html)
	H3	DRS-H3 (DSHypo 03) ^a	ALWKDVLKKIGTVALH AGKAALGAA ADTISQGG	P84598 (http://www.uniprot.org/uniprot/P84598.html)
	H4	DRS-H4 (DSHypo 04) ^a	GLWSTIKQKGKEAAIA AKAAGKAVLNA ASEAL-NH ₂	P84599 (http://www.uniprot.org/uniprot/P84599.html)
	H5	DRS-H5 (DSHypo 05) ^a	GLWSTIKQKGKEAAIA AKAAGQAALGAL -NH ₂	P84600 (http://www.uniprot.org/uniprot/P84600.html)
	H6	DRS-H6 (DSHypo 06) ^a	GLWSTIKQKGKEAAIA AKAAGQAVL NSASEAL-NH ₂	P84601 (http://www.uniprot.org/uniprot/P84601.html)
	H7	DRS-H7 (DSHypo 07) ^a	GLWSTIKQKGKEAAIA AKAAGQAALNA ASEAL-NH ₂	P84880 (http://www.uniprot.org/uniprot/P84880.html)
	H8	DRS-H8 (DSN-2) ^a	ALWKSLLKNVGA AKGKAALNAV TPDMVNQ	Q0VZ36 (http://www.uniprot.org/uniprot/Q0VZ36.html)
<i>P. oreades</i>	O1	DRS-O1 (DSO1)	GLWSTIKQKGKEAAIA AKAAGQAALGAL -NH ₂	P83637 (http://www.uniprot.org/uniprot/P83637.html)
<i>P. sauvagii</i>	S1	DRS-S1 (DS I)	ALWKTMLKKLGT MALHAGKAALGAA ADTISQGTQ	P24302 (http://www.uniprot.org/uniprot/P24302.html)
	S2	DRS-S2 (DS II)	ALWFTMLKKLGT MALHAGKAALGAA ANTISQGTQ	P80278 (http://www.uniprot.org/uniprot/P80278.html)
	S3	DRS-S3 (DS III)	ALWKNMLKGIGK LAGKAALGAV KTLVGAE	P80279 (http://www.uniprot.org/uniprot/P80279.html)
	S4	DRS-S4 (DS IV)	ALWMTLLKVLKA AKALNAV LVGANA	P80280 (http://www.uniprot.org/uniprot/P80280.html)
	S5	DRS-S5 (DS V)	GLWSKIKTAGKSVAKA AKAAVKAV TNAV	P80281 (http://www.uniprot.org/uniprot/P80281.html)
	S6	DRS-S6 (DS VI)	GLWSKIKTAGKEAAKA AKAAGKAALNAV SEAI	Q7T3K9 (http://www.uniprot.org/uniprot/Q7T3K9.html)
	S7	DRS-S7 (DS VII)	GLWKSLLKNVGA AKGKAALNAV TPDMVNQ	Q7T3K8 (http://www.uniprot.org/uniprot/Q7T3K8.html)
	S8	DRS-S8 (DS VIII)	ALWKTMLKKLGTVALH AGKAALGAA ADTISQ	Q7T3K7 (http://www.uniprot.org/uniprot/Q7T3K7.html)
	S9	DRS-S9 (S9)	GLRSKIWLWVLLMI WQESNK PKKM	Q1EN15 (http://www.uniprot.org/uniprot/Q1EN15.html)
	S11	DRS-S11 (S11)	ALWKTLLKG AGKVF GHVAKQFLGSQGPES	Q1EN13 (http://www.uniprot.org/uniprot/Q1EN13.html)
	S12	DRS-S12 (S12)	GLWSKIKEAAKT AGKMA MGFVNDMVGQ	Q1EN12 (http://www.uniprot.org/uniprot/Q1EN12.html)
	S13	DRS-S13 (S13)	GLRSKIKEAAKT AGKMA LGFVNDMAGEQ	Q1EN11 (http://www.uniprot.org/uniprot/Q1EN11.html)

Table 4 continued

Species	Dermaseptin	Abbreviation	Peptide	Digital abstract
<i>P. tarsi</i>	T1	DRS-T1 (DStar 01)	GLWSKIKETGKE AAKAAGKA ALNKIAEAV-NH ₂	P84921 (http://www.uniprot.org/uniprot/P84921.html)
	T2	DRS-T2 (DStar 02)	ALWKDILKNV GKAAGKAV LNTVDTMNVQ-NH ₂	P84922 (http://www.uniprot.org/uniprot/P84922.html)
	T3	DRS-T3 (DStar 03)	GLFKTLIK GAGKML GHVAKQFLGSQQGPES	P84923 (http://www.uniprot.org/uniprot/P84923.html)
	T4	DRS-T4 (DStar 04)	ALWKDILKN AGKAALNE INQIVQ-NH ₂	P84924 (http://www.uniprot.org/uniprot/P84924.html)
	T5	DRS-T5 (DStar 05)	GLWSKIKEAAKT AGKAAMGFV NEMV-NH ₂	P84925 (http://www.uniprot.org/uniprot/P84925.html)
	T6	DRS-T6 (DStar 06)	ALWKNMLKGIGK LAGQAALGAV KTLVGA	P84926 (http://www.uniprot.org/uniprot/P84926.html)
	T7	DRS-T7 (DStar 07)	ALWKDVLKKIGTVAL HAGKAALGAV ADTISQ-NH ₂	P84927 (http://www.uniprot.org/uniprot/P84927.html)

The bold residues belong to the consensus motif. Names used are in accordance with the nomenclature proposed by Amiche et al. (2008). Abbreviations used before the new nomenclature are in brackets

^a New names proposed for peptides isolated from *P. azurea* and *P. hypochondrialis* according to the nomenclature rules proposed by Amiche et al. (2008). Before *P. azurea* was renamed by Caramaschi (2006) the species used to be named as *P. hypochondrialis azurea* (Calderon et al. 2009b)

^b The C-terminal amidation given is based on similarity and not on experimental findings

2000). Observation of bacterial cells by reflected light fluorescence microscopy after DNA-staining supports the cell-killing mechanism based upon the alteration of PM permeability rather than PM solubilization, possibly related to ion-conducting channels through the PM (Amiche et al. 2000).

The antimicrobial activity spectrum of dermatoxin includes stains of wall-less and Gram-positive bacteria, and also, though to a lesser extent, Gram-negative bacteria. The wall-less bacteria: *Acholeplasma laidlawii*, *Spiroplasma melliferum*; Gram-negative bacteria: *Sinorhizobium meliloti*; and Gram-positive bacteria: *Bacillus megaterium* and *Corynebacterium glutamicum* are susceptible to DRT-B1. The Gram-negative bacteria: *Burkholderia cepacia*, *Pseudomonas aeruginosa* and *Salmonella typhimurium*; and Gram-positive bacteria: *Staphylococcus aureus* are resistant to DRT-B1 (Amiche et al. 2000). Amiche et al. (2000) argue that the higher resistance against dermatoxin by Gram-negative bacteria might be related to the presence of a second PM in their envelope.

Distinctin

Distinctin, a prototypical member of a family of antimicrobial peptides, is a 5.4-kDa heterodimeric antimicrobial peptide from *Phyllomedusa distincta* with two linear peptide chains of 22 and 25 amino acid residues joined by a single intermolecular disulfide bond (Fig. 2) (Batista et al. 2001). To date, only the peptide that shows sequence similarity to the distinctin chain B was the distinctin-like peptide (ppdis-H1) from *P. azurea*. They have in common a high conserved N-terminal sequence NLVSG[A]-LIEA[G]RKYL (Table 6). Heterodimeric structures joined by a single intermolecular S-S bond were reported in

invertebrates' neurotoxins inhibiting neurotransmitter release, imperatoxin I, and L-bungarotoxins (Kwong et al. 1995). CD and FTIR studies indicate that this molecule adopts, in aqueous solution, a structure with a significant percentage of antiparallel β -sheet (Batista et al. 2001) whereas the CD and FTIR spectroscopy experimental data indicate that the distinctin heterodimer adopts helical conformations with a lower β -sheet content in PM environments (Serra et al. 2008). NMR experiments indicated that the peptide helices are oriented almost parallel to the PM surface, thereby reflecting the amphipathic distribution of apolar and hydrophilic amino acid side chains (Bechinger 1999; Bechinger et al. 2001; Resende et al. 2008). According to Serra et al. (2008), the experimental output recorded so far for the distinctin mechanism of insertion into PMs is compatible with a barrel-stave pore (Serra et al. 2008).

The antimicrobial activity spectrum of distinctin includes strains of the Gram-negative bacteria: *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Serratia marcescens*, and *Stenotrophomonas maltophilia*; and Gram-positive bacteria: *Enterococcus faecalis*, *E. faecium*, *Staphylococcus aureus*, and *Streptococcus pneumoniae* (Batista et al. 2001; Giacometti et al. 2006; Serra et al. 2008).

Phylloseptin

Phylloseptins are AMPs of 19–21 residues (1.7–2.1 kDa) found in the skin secretions of the *Phyllomedusa azurea*, *P. bicolor*, *P. burmeisteri*, *P. hypochondrialis*, *P. oreades*, *P. rohdei*, *P. tarsi*, and *P. tomopterna* (see Table 2). Their common structural features include a highly conserved sequence FLSLI[L]P in the N-terminal region and

C-terminal amidation (Leite et al. 2005) (see Table 7). Phylloseptins exemplify that considerable differences in biological activity may rely upon minor modifications of the primary sequence of model compounds, even when overall amino acid composition is kept constant (Wieprecht et al. 1997). Phylloseptin peptides adopt α -helical conformations in PM environments stabilized by electrostatic interactions of the helix dipole and others, such as hydrophobic and capping interactions (Resende et al. 2008). AFM experiments indicated that the bacteriolytic properties of these peptides might be related to their disruptive action on the PM characterized by a number of bubble-like formations, preceding every cell lysis (Leite et al. 2005).

The antimicrobial activity spectrum of phylloseptins includes strains of the Gram-negative bacteria: *Acinetobacter calcoaceticus*, *Escherichia coli*, and *Pseudomonas aeruginosa* (Leite et al. 2005; Resende et al. 2008); Gram-positive bacteria: *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, and *Streptococcus agalactiae*; Fungi: *Candida albicans* (Resende et al. 2008); and Protozoa: *Leishmania amazonensis* (promastigotes) (Kückelhaus et al. 2009), *Plasmodium falciparum* (rings, trophozoites, and schizonts) (Kückelhaus et al. 2009), and *Trypanosoma cruzi* (trypomastigotes) (Leite et al. 2005).

Besides, this peptide exhibited negligible effects on red blood cells (Leite et al. 2005) and some toxic effect to mammalian cells only at very high concentrations (Kückelhaus et al. 2006, 2009).

Phylloxin

Phylloxin is a family of cationic and amphipathic peptides that have very similar N-terminal preprosequences followed by marked C-terminal domains. Two phylloxins,

19 residues long from *Phyllomedusa* skin, were identified. Phylloxin B1 from *P. bicolor* (PLX-B1) (Pierre et al. 2000; Chen et al. 2005b) and phylloxin S1 from *P. sauvagii* (PLX-S1) (Chen et al. 2005a) (Table 8). The primary structures of the two phylloxins are extremely conserved, exhibiting only one conservative amino acid substitution at position 17, containing M or V for PLX-B1 and PLX-S1, respectively.

Phylloxins are members of the family of preprodermorphin/dermaseptins-derived peptides (see Table 3). Despite the considerable similarity between the phylloxin polypeptide precursor and the preprodermaseptin-B1 (Pierre et al. 2000), there is no homology between the phylloxin and dermaseptins (Pierre et al. 2000), in spite of some resemblance to the levitide-precursor fragment and the xenopsin-precursor fragment, two AMPs isolated from *Xenopus laevis* (Poulter et al. 1988; Fleury et al. 1996; Pierre et al. 2000).

The preprophylloxin consists of a putative signal peptide of 20–23 residues, a typical propeptide convertase processing site (–KR–), an intervening acidic amino acid residue-rich spacer peptide, a second typical processing site and a terminal antimicrobial peptide-encoding domain (the hypervariable domain) (Chen et al. 2005a).

Circular dichroism (CD) spectra of phylloxin in low polarity medium, mimicking the lipophilicity of the PM of target microorganisms, indicated 60–70% α -helical conformation, and predictions of secondary structure suggested that the peptide can be configured as an amphipathic helix spanning residues 1–19 (Pierre et al. 2000).

The antimicrobial activity spectrum of phylloxin includes the strains of the wall-less bacteria: *Acholeplasma laidlawii* and *Spiroplasma melliferum*; Gram-negative bacteria: *Escherichia coli*; and Gram-positive bacteria:

Table 5 Primary structures of dermatoxins from *Phyllomedusa* species

Species	Dermatoxin ^a	Abbreviation ^a	Sequence	Digital abstract
<i>P. bicolor</i>	B1	DRT-B1	SLGSFL LKGVG TTLASV GKVVSDQ FG KLLQAGQG	Q9PT75 (http://www.uniprot.org/uniprot/Q9PT75.html)
<i>P. sauvagii</i>	S1	DRT-S1	ALG TLLKGVG SAVAV VGK MVAD Q FG KLLQAGQG	Q5DVA5 (http://www.uniprot.org/uniprot/Q5DVA5.html)
<i>P. tarsius</i>	T1	DRT-T1 (DStar 08)	SLRG FLKGVG TALAG VGKVVADQ FD KLLQAGQ -NH ₂	P84928 (http://www.uniprot.org/uniprot/P84928.html)

The bold residues are conserved

^a The peptides are named according to the nomenclature proposed by Amiche et al. (2008), the original nomenclature are in brackets

Table 6 Primary structures of distinctin and distinctin-like peptide from *P. azurea*

Species	Name	Sequence	Digital abstract
<i>P. distincta</i>	Distinctin Chain B	NLVSGLIEARKYLE QLHR KLKNCKV	–
<i>P. azurea</i>	Distinctin-like (ppdis-H1)	NLVSALIEGRKYL KNVL KL NRL KEKNKAKNSK ENN	Q17UZ0 (http://www.uniprot.org/uniprot/Q17UZ0.html)

The bold residues are conserved

Micrococcus luteus. The Gram-negative bacteria: *Pseudomonas aeruginosa*, *Rhizobium meliloti*, and *Salmonella typhimurii*; and Gram-positive bacteria: *Corynebacterium glutamicum* and *Staphylococcus aureus* show resistance to phylloxin B1 (Pierre et al. 2000).

Plasticin

Plasticins are 23 long-residue GL-rich dermaseptin-related peptides with very similar amino acid sequences, hydrophobicities, and amphipathicities, but differ in their PM damaging properties and structuration (i.e., destabilized helix states, β -hairpin, β -sheet, and disordered states) at anionic and zwitterionic PM interfaces (El Amri et al. 2006). To date, two plasticins were described in *Phyllomedusa* secretions




Fig. 2 Primary structure of distinctin from *P. distincta*

(Table 9): the cationic peptide plasticin-B1 (PTC-B1) from *P. bicolor*, which was previously described with the name PBN2 (Vanhoye et al. 2004), and plasticin-S1 (PTC-S1) from *P. sauvagii*, which was previously described as dermaseptin-S10 (Amiche et al. 2008).

Structural malleability of plasticins in aqueous solutions and parameters governing their ability to fold within β -hairpin-like structures were analyzed through CD and FTIR spectroscopic studies completed by molecular dynamics simulations in polar mimetic media (El Amri et al. 2006).

All plasticins present a turn region that does not always result in folding into a β -hairpin-shaped conformation. Residue at position 8 plays a major role in initiating the folding, while position 12 is not critical (Bruston et al. 2007). Conformational stability has no major impact on antimicrobial efficacy (Bruston et al. 2007). However, preformed β -hairpin in solution may act as a conformational lock that prevents the switch to α -helical structure (Bruston et al. 2007). This lock lowers the antimicrobial efficiency and explains subtle differences in potencies of the most active antimicrobial plasticins (Bruston et al. 2007).

Table 7 Primary structures of phylloseptins from *Phyllomedusa* species

Species	Phylloseptin ^a	Abbreviation ^a	Peptide	Digital abstract
<i>P. azurea</i>	AZ1	PLS-AZ1 (PS-2)	FLSL IPHAINAVSTLVVHF-NH ₂	P85881 (http://www.uniprot.org/uniprot/P85881.html)
	AZ2	PLS-AZ2 (PS-7)	FLSL IPHAINAVSAIAKHF-NH ₂	P85882 (http://www.uniprot.org/uniprot/P85882.html)
	AZ3	PLS-AZ3 (PS-8)	FLSLLP TAINAVSALAKHF-NH ₂	P85883 (http://www.uniprot.org/uniprot/P85883.html)
	AZ4	PLS-AZ4 (PS-12)	FLSLLP SIVSGAVSLAKKL-NH ₂	Q17UY9 (http://www.uniprot.org/uniprot/Q17UY9.html)
	AZ5	PLS-AZ5 (PS-13)	FLSL IPHAINAVGVHAKHF-NH ₂	P84938 (http://www.uniprot.org/uniprot/P84938.html)
	AZ6	PLS-AZ6 (PS-14)	FLSL IPAAISAVSALADHF-NH ₂	P84939 (http://www.uniprot.org/uniprot/P84939.html)
	AZ7	PLS-AZ7 (PS-15)	LLSLV PHAINAVSAIAKHF-NH ₂	Q0VKG9 (http://www.uniprot.org/uniprot/Q0VKG9.html)
<i>P. bicolor</i>	B1	PLS-B1 (PBN-1)	FLSL IPHIVSGVAALAKHL-NH ₂	Q800R3 (http://www.uniprot.org/uniprot/Q800R3.html)
<i>P. burmeisteri</i>	BU1	PLS-BU1 (Bu-1)	FLIS IPYSASIGGTATLTGTA-NH ₂	P86282 (http://www.uniprot.org/uniprot/P86282.html)
	BU2	PLS-BU2 (Bu-2)	FLLSL PHLASGLASLVLSK-NH ₂	P86283 (http://www.uniprot.org/uniprot/P86283.html)
<i>P. hypochondrialis</i>	H1	PLS-H1 (PS-1)	FLSL IPHAINAVSAIAKHN-NH ₂	P84566 (http://www.uniprot.org/uniprot/P84566.html)
	H2	PLS-H2 (PS-2)	FLSL IPHAINAVSTLVVHF-NH ₂	P84567 (http://www.uniprot.org/uniprot/P84567.html)
	H3	PLS-H3 (PS-3)	FLSL IPHAINAVSALANHG-NH ₂	P84568 (http://www.uniprot.org/uniprot/P84568.html)
	H4	PLS-H4 (PS-6)	-- SL IPHAINAVSAIAKHF-NH ₂	P84571 (http://www.uniprot.org/uniprot/P84571.html)
	H5	PLS-H5 (PS-7)	FLSL IPHAINAVSAIAKHF-NH ₂	P84572 (http://www.uniprot.org/uniprot/P84572.html)
	H6	PLS-H5 (PS-8)	FLSLLP TAINAVSALAKHF-NH ₂	Q0VZ41 (http://www.uniprot.org/uniprot/Q0VZ41.html)
	H7	PLS-H6 (PS-9)	FLG LLPSIVSGAVSLVKKLG-NH ₂	Q0VZ38 (http://www.uniprot.org/uniprot/Q0VZ38.html)
	H8	PLS-H7 (PS-10)	FLSLLP SLVSGAVSLVKKL-NH ₂	Q0VZ39 (http://www.uniprot.org/uniprot/Q0VZ39.html)
	H9	PLS-H8 (PS-11)	FLSLLP SLVSGAVSLVKIL-NH ₂	Q0VZ40 (http://www.uniprot.org/uniprot/Q0VZ40.html)
<i>P. oreades</i>	O1	PLS-O1 (PS-4)	FLSL IPHAINAVSTLVVHSG-NH ₂	P84569 (http://www.uniprot.org/uniprot/P84569.html)
	O2	PLS-O2 (PS-5)	FLSL IPHAINAVSAIAKHS-NH ₂	P84570 (http://www.uniprot.org/uniprot/P84570.html)
<i>P. tarsiis</i>	T1	PLS-T1 (PStar 01)	FLSL IPKIAGGIASLVKNL-NH ₂	P84929 (http://www.uniprot.org/uniprot/P84929.html)
	T2	PLS-T2 (PStar 02)	FLSL IPHIATGIAALAKHL-NH ₂	P84930 (http://www.uniprot.org/uniprot/P84930.html)
	T3	PLS-T3 (PStar 03)	FFSM IPKIATGIASLVKNL-NH ₂	P84931 (http://www.uniprot.org/uniprot/P84931.html)
<i>P. tomopterna</i>	TO1	PLS-TO1 (PS-8)	FLSL IPHAINAVSALAKHF-NH ₂	P85447 (http://www.uniprot.org/uniprot/P85447.html)

The bold residues are conserved

^a The peptides are named according to the nomenclature proposed by Amiche et al. (2008), the original nomenclature are in brackets

The antimicrobial activity spectrum of PTC-B1 includes strains of Gram-negative bacteria: *Clostridium perfringens*, *Escherichia coli*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Pseudomonas aeruginosa*, *Salmonella enteritidis*, and *Vibrio cholerae*; Gram-positive bacteria: *Bacillus megaterium*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Staphylococcus haemolyticus*, and *Streptococcus pneumoniae*; and Fungi: *Candida albicans* and *Saccharomyces cerevisiae* (Vanhoye et al. 2004). Haemolysis was not detected (Vanhoye et al. 2004). The Gram-positive bacteria *Burkholderia cepacia* is resistant to PTC-B1 (Vanhoye et al. 2004). Without C-terminus amidation of PTC-B1, antimicrobial activity ceases, except for *Staphylococcus aureus* and *S. haemolyticus* that are more affected by PTC-B1 40–48 folds than the PTC-B1 amide. Hemolytic activity was recorded (Vanhoye et al. 2004), supporting data from Matsuzaki (2009) in that the reduction of the peptide positive net charge reduces its antimicrobial activity.

Skin polypeptide YY

Related peptides that belong to the Neuro Peptide Y (NPY) family (36 residues length) which also include peptide YY (PYY), the tetrapod pancreatic polypeptide (PP), and the fish pancreatic peptide Y (PY) have been found in various vertebrate groups (Lazarus and Attila 1993; Cerdá-Reverter and Larhammar 2000). These peptides integrate a variety of important regulatory functions, e.g., sympathetic vascular control, central regulation of endocrine and autonomic function, food intake, circadian rhythm, histamine release from isolated mast cells, and increase of intracellular Ca^{2+} in many cell types (Yasuhara et al. 1981).

In *Phyllomedusa*, the only peptide pharmacologically and structurally related to NPY described was the skin polypeptide YY (SPYY) (Mor et al. 1994a). SPYY was

purified from acetic extracts of *Phyllomedusa bicolor* skin (Mor et al. 1994b), exhibiting 94% of similarity with PYY from the frog *Rana ridibunda* (Conlon et al. 1992) and 86% of similarity with human PYY (Kohri et al. 1993) (Table 10). The primary structures of the two frog NPYs are highly conserved presenting only two amino acid substitutions (positions 7 and 18) (Table 10).

Besides the NPY–RP primary structures similarity, other common features are the C-terminal amidation and the tertiary structure, known as the PP-fold (Erspamer et al. 1962). The PP-fold consists of two antiparallel helices: an N-terminal polyproline helix spanning residues 1–14 and a long amphipathic C-terminal α -helix.

As other peptide hormones of the amphipathic helix class with PM disordering or disruptive properties, such as glucagon (Jones et al. 1978), SPYY also shows PM lysing activity against pathogenic microbes. SPYY shows antibiotic activity against strains of Gram-negative bacteria: *Aeromonas caviae* and *Escherichia coli*; Gram-positive bacteria: *Enterococcus faecalis* and *Nocardia brasiliensis*; Fungi: *Arthroderma simii*, *Aspergillus fumigatus*, *A. niger*, *Microsporium canis*, and *Tricophyton rubrum*; and Protozoa: *Leishmania major* promastigotes. Reversibility of inhibition was not reported for any strain (Vouldoukis et al. 1996).

Therapeutic peptide antibiotics

One of the greatest accomplishments of modern medicine was the development of antibiotic therapies for potentially fatal infections by multidrug-resistant pathogenic microorganisms. Unfortunately, in the past two decades, the discovery and development of novel antibiotics decreased while pathogen resistance to those currently available increased (Li et al. 2006).

Table 8 Primary structures of phylloxins from *Phyllomedusa* species

Species	Phylloxin	Abbreviation	Sequence	Digital abstract
<i>P. bicolor</i>	B1	PLX-B1	GWMSKIASGIGTFLSGMQQ -NH ₂	P81565 (http://www.uniprot.org/uniprot/P81565.html)
<i>P. sauvaigi</i>	S1	PLX-S1	GWMSKIASGIGTFLSGVQQ	Q5DVA6 (http://www.uniprot.org/uniprot/Q5DVA6.html)

The bold residues are conserved

Table 9 Primary structures of plasticins from *Phyllomedusa* species

Species	Plasticin ^a	Abbreviation ^a	Sequence	Digital abstract
<i>P. bicolor</i>	B1	PTC-B1 (PBN2)	GLVTSLLIKGAGKLLGGLFGSVTG -NH ₂	Q800R4 (http://www.uniprot.org/uniprot/Q800R4.html)
<i>P. sauvaigi</i>	S1	PTC-S1 (DS 10)	GLVSDLLSTVTGLLGNLGGGGLKKI	Q1EN14 (http://www.uniprot.org/uniprot/Q1EN14.html)

The bold residues are conserved

^a The peptides are named according to the nomenclature proposed by Amiche et al. (2008), the original nomenclature are in brackets

The emergence and rapid spread of extremely multiresistant pathogenic microorganisms, the increased use of immunosuppressive therapies, and the association with HIV co-infection present a serious public health problem with worrisome mortality and morbidity rates (e.g., *Cryptococcus*, *Cryptosporidium*, and *Leishmania*) (Abu-Raddad et al. 2006; Pukkila-Worley and Mylonakis 2008; Rivas et al. 2009; Vaara 2009). Limited therapeutic options against these pathogens stimulated the prospection of new bioactive molecules from the biodiversity as a source for more efficient (low toxicity and major potency) mechanisms of microorganism killing (Calderon et al. 2009a; Vaara 2009). This information is important to subsidize the development of new chemicals with structural characteristics for large-scale production by the pharmaceutical industry at a feasible cost. The sources from the biodiversity, such as the skin of several frogs' species, e.g., as *Phyllomedusa* and other vertebrate and invertebrate animals, plants, and microorganisms, have proved to be an inexorable source of antimicrobial molecules, with a broad spectra of activity (Calderon et al. 2009a), in which the AMPs have highlights in their potential therapeutical application (Hancock 1997; Hancock and Lehrer 1998; Koczulla and Bals 2003; Gomes et al. 2007). During the last 40 years of antimicrobial peptides research, lots of information were generated, with insights about key issues of the peptide antimicrobial potency and selectivity, allowing the development of synthetic rational designed peptides with improved antimicrobial activity (Andrä et al. 2007) and less toxicity to mammalian cells (Hawrami et al. 2008) by the application of site-directed mutation, combinatorial chemistry, and chemical synthesis techniques (Hilpert et al. 2006; Edwards 2007; Andrä et al. 2007). In order to develop new peptide antibiotics, synthetic changed peptides were designed including: improvement of positive charge, decreasing-induced resistance in bacteria (Zasloff 2002; Andreu and Rivas 1998; Hancock and Lehrer 1998; van't et al. 2001; Moellering 2003; Yeaman and Yount 2003); lower molecular mass by reduced number of amino acid residues (Hancock 1997; Boman 2003; Perron et al. 2006; Peschel and Sahl 2006; Bisht et al. 2007; Haug et al. 2007); and insertion of unnatural amino acids (Edwards 2007). All peptide modifications might offer significant

advantages over native AMPs as therapeutical agents (Rotem and Mor 2009).

According to Marr et al. (2006), therapeutic peptide antibiotics will have advantages over conventional antibiotics due their diverse potential applications, such as single antimicrobials, in combination with other antibiotics for a synergistic effect, or as immunomodulatory and/or endotoxin-neutralizing compounds (Zasloff 2002). In particular, the most potent agents have unusually broad spectra of activity against most Gram-negative and Gram-positive bacteria, and also to fungi and even a variety of viruses. Although the potency of these AMPs against the more susceptible pathogens is generally less than certain conventional antibiotics, one of their advantages is their ability to kill multidrug-resistant bacteria at similar concentrations (Marr et al. 2006). Compared with conventional antibiotics, these bacteria-killing peptides are extremely rapid and attack multiple bacterial cellular targets (Brogden 2005).

Despite their obligatory interaction with the PM, some peptides are able to perforate PMs at their minimal inhibition concentration (MIC), a number of peptides translocate across the PM and affect cytoplasmic processes, including inhibition of macromolecular synthesis, particular enzymes or cell division, or the stimulation of autolysis (Marr et al. 2006). Minimal inhibitory concentrations and minimal bactericidal concentrations often coincide (less than a two-fold difference), indicating that killing is generally bactericidal, a highly desirable mode of action (Marr et al. 2006). Furthermore, peptides are not hindered by the resistance mechanisms that occur with currently used antibiotics (Zhang et al. 2005). Indeed, killing can occur synergistically with other peptides and conventional antibiotics, helping overcome some barriers that resistant bacteria have against currently used antibiotics (Marr et al. 2006).

Nanobiotechnological application of *Phyllomedusa* AMPs

In recent years, significant efforts were devoted to the development of nanotechnological tools capable of

Table 10 Primary structures of polypeptide YY from *Phyllomedusa bicolor*, *Rana ridibunda*, and human

Species	Name	Sequence	Digital abstract
<i>P. bicolor</i>	Skin polypeptide YY (SPYY)	Y PPK E SPGEDASPEEMNKYL T ALRHYINLVTRQRY-NH ₂ ^a	P80952 (http://www.uniprot.org/uniprot/P80952.html)
<i>R. ridibunda</i>	Peptide YY-like (PYY)	Y PPK E NPGEDASPEEMTKYL T ALRHYINLVTRQRY-NH ₂	P29204 (http://www.uniprot.org/uniprot/P29204.html)
<i>H. sapiens</i>	Peptide YY (PYY)	Y PIK E APGEDASPEELNRYASLRHYLN L VTRQRY-NH ₂	P10082 (http://www.uniprot.org/uniprot/P10082.html)

The bold residues are conserved

^a The C-terminal amidation given is based on similarity and not on experimental findings

enhancing the assembly and immobilization of biomolecules in a synergistic way in biomedical devices (Huguenin et al. 2005; Siqueira et al. 2006; Zucolotto et al. 2006; Zampa et al. 2007; Zucolotto et al. 2007). Nanotechnology focuses on formulating therapeutic agents in biocompatible nanocomposites, such as nanoparticles, nanocapsules, micellar systems, and conjugates. As these systems are often polymeric and submicron sized, they have multifaceted advantages in drug delivery.

The structural and physico-chemical properties of the AMPs, such as the presence of a α -helix structure and distribution of positive charges along the chain, allowed their use as active material in the development of bio-nanostructures with potential application on therapeutics by the pharmaceutical industry and diagnosis (Zampa et al. 2009). These structures include cationic nanoparticles, formed by the conjugation of cholesterol and AMPs, able to cross the blood–brain barrier for treatment of fatal *Cryptococcal* meningitis in patients with late-stage HIV infection (Wang et al. 2010); nanostructured thin films with immobilized AMPs as an agent intended to combat and prevent infection and formation of *Staphylococcus* biofilm (slimelike communities) related implant failure (Shukla et al. 2009); or as sensor elements for detection of *Leishmania* cells using cyclic voltammetry (Zampa et al. 2009).

The use of the AMPs through nanotechnological innovation approach could provide an entirely novel way to treat and prevent infection and new systems for the detection and identification of infectious parasites.

Final considerations

The *Phyllomedusa* skin is an abundant source of peptides that show a broad spectrum of activities, including antimicrobial, neuroactive, and smooth muscle activity. From the first *Phyllomedusa* peptide isolated and characterized to date, more than 200 peptides from *Phyllomedusa* species have had their primary structure characterized, and several of them had its biological activities evaluated, mainly in the last 10 years. Until then, many efforts have been carried out in order to use the AMPs in the development of new infection-fighting drugs applicable to new treatments of nosocomial infections and multidrug-resistant infections (Amiche et al. 2000), due to the skill of the AMPs to kill drug resistant strains of Gram-positive bacteria, Gram-negative bacteria, yeast, protozoa, and viruses, by a mechanism unlikely to induce antibiotic-resistance. The development of new antimicrobials based on AMPs hold promises to medicine at the end of the classical antibiotic age by the emergence of the multidrug-resistant microorganisms.

Even with the expected advantages in the use of AMPs as antibiotics, several impediments to therapeutic peptides arise. According to Marr et al. (2006), the main problems at the present moment are the cost of manufacturing peptides, which is economically unfeasible for the amounts of AMPs needed compared to other antibiotics, preventing the widespread clinical use of AMPs as a common antibiotic, and the shortage of studies thoroughly examining systemic peptide pharmacodynamic and pharmacokinetic issues, including peptide aggregation problems, the in vivo half-life of peptides (and particularly their susceptibility to mammalian proteases), and the required dosing frequency.

Due to the specific characteristics of the AMPs, that differentiate them from other antibiotics, the development of new strategies for the therapeutic use of AMPs in medicine are necessary in order to reduce the amount of AMPs necessary to promote the therapeutic infection suppression effect, including the addition of striking affinity to specific targets, efficiency at very low concentrations and negligible toxicity. In this way, nanotechnology has become an efficient and viable alternative to promote the therapeutic application of AMPs. Nanotechnology could provide new ways to use lower amounts of AMPs with extreme efficiency in the infection suppression, by improving the cell, tissue, or organ's specific biodistribution and increasing AMP potency by the association with nanotechnological structures. It is expected that in the forthcoming years nanotechnology will promote the emergence of new products for control and prevention of multidrug-resistance microbe infection arising from the identification and analysis of AMPs from South American frog biodiversity.

Acknowledgments The authors are grateful to the Ministry of Science and Technology (MCT), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Financiadora de Estudos e Projetos (FINEP), Fundação de Tecnologia do Acre (FUNTAC/FDCT), Coordenação de Aperfeiçoamento de Nível Superior (CAPES) – Projeto NanoBiotec, Secretary of Development of the Rondonia State (PRONEX/CNPq) for financial support and Priscila Cerviglieri for linguistic advice.

References

- Abu-Raddad LJ, Patnaik P, Kublin JG (2006) Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. *Science* 314:1603–1606
- Amiche M, Ducancel F, Lajeunesse E, Boulain JC, Menez A, Nicolas P (1993) Molecular cloning of a cDNA encoding the precursor of adenoregulin from frog skin. Relationships with the vertebrate defensive peptides, dermaseptins. *Biochem Biophys Res Commun* 191:983–990
- Amiche M, Ducancel F, Mor A, Boulain JC, Menez A, Nicolas P (1994) Precursors of vertebrate peptide antibiotics dermaseptin b and adenoregulin have extensive sequence identities with

- precursors of opioid peptides dermorphin, dermenkephalin, and deltorphins. *J Biol Chem* 269:17847–17852
- Amiche M, Delfour A, Nicolas P (1998) Opioid peptides from frog skin. *EXS* 85:57–71
- Amiche M, Seon AA, Pierre TN, Nicolas P (1999) The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. *FEBS Lett* 456:352–356
- Amiche M, Seon AA, Wroblewski H, Nicolas P (2000) Isolation of dermatoxin from frog skin, an antibacterial peptide encoded by a novel member of the dermaseptin genes family. *Eur J Biochem* 267:4583–4592
- Amiche M, Ladram A, Nicolas P (2008) A consistent nomenclature of antimicrobial peptides isolated from frogs of the subfamily Phyllomedusinae. *Peptides* 29:2074–2082
- Ammar B, Perianin A, Mor A, Sarfat G, Tissot M, Nicolas P, Giroud JP, Roch-Arveiller M (1998) Dermaseptin, a peptide antibiotic, stimulates microbicidal activities of polymorphonuclear leukocytes. *Biochem Biophys Res Commun* 247:870–875
- Anastasi A, Falconieri Erspamer G (1970) Occurrence of phyllomedusin, a physalaemin-like decapeptide, in the skin of *Phyllomedusa bicolor*. *Experientia* 26:866–867
- Anastasi A, Bertaccini G, Erspamer V (1966) Pharmacological data on phyllokinin (bradykinyl-isoleucyl-tyrosine α -sulphate) and bradykinyl-isoleucyl-tyrosine. *Br J Pharmacol* 27:479–485
- Anastasi A, Bertaccini G, Cei JM, De Caro G, Erspamer V, Impicciatore M (1969) Structure and pharmacological actions of phyllocaerulein, a caerulein-like nonapeptide: its occurrence in extracts of the skin of *Phyllomedusa sauvagei* and related *Phyllomedusa* species. *Br J Pharmacol* 37:198–206
- Andrä J, Monreal D, Martinez de Tejada G, Olak C, Brezesinski G, Sanchez Gomez S, Goldmann T, Bartels R, Brandenburg K, Moriyon I (2007) Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. *J Biol Chem* 282:14719–14728
- Andreu D, Rivas L (1998) Animal antimicrobial peptides: an overview. *Biopolymers* 47:415–433
- Barra D, Simmaco M (1995) Amphibian skin: a promising resource for antimicrobial peptides. *Trends Biotechnol* 13:205–209
- Barra D, Falconieri Erspamer G, Simmaco M, Bossa F, Melchiorri P, Erspamer V (1985) Rohdei-litorin: a new peptide from the skin of *Phyllomedusa rohdei*. *FEBS Lett* 182:53–56
- Barra D, Mignogna G, Simmaco M, Pucci P, Severini C, Falconieri Erspamer G, Negri L, Erspamer V (1994) [D-Leu²]deltorphin, a 17 amino acid opioid peptide from the skin of the Brazilian hylid frog, *Phyllomedusa burmeisteri*. *Peptides* 15:199–202
- Batista CVF, Rosendo da Silva L, Sebben A, Scaloni A, Ferrara L, Paiva GR, Olamendi-Portugal T, Possani LD, Bloch C Jr (1999) Antimicrobial peptides from the Brazilian frog *Phyllomedusa distincta*. *Peptides* 20:679–686
- Batista CVF, Scaloni A, Rigden DJ, Silva LR, Romero AR, Dukor R, Sebben A, Talamo F, Bloch C Jr (2001) A novel heterodimeric antimicrobial peptide from the tree-frog *Phyllomedusa distincta*. *FEBS Lett* 494:85–89
- Bechinger B (1999) The structure, dynamics and orientation of antimicrobial peptides in membranes by solid-state NMR spectroscopy. *Biochim Biophys Acta* 1462:157–183
- Bechinger B (2004) Membrane-lytic peptides. *Crit Rev Plant Sci* 23:271–292
- Bechinger B (2005) Detergent-like properties of magainin antibiotic peptides: a 31P solid-state NMR study. *Biochim Biophys Acta* 1712:101–108
- Bechinger B, Lohner K (2006) Detergent-like action of linear cationic membrane-active antibiotic peptides. *Biochim Biophys Acta* 1758:1529–1539
- Bechinger B, Skladnev DA, Ogrel A, Li X, Rogozhkina EV, Ovchinnikova TV, O’Neil JD, Raap J (2001) 15N and 31P solid-state NMR investigations on the orientation of zervamicin II and alamethicin in phosphatidylcholine membranes. *Biochemistry* 40:9428–9437
- Belaid A, Aouni M, Khelifa R, Trabelsi A, Jemmali M, Hani K (2002) In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. *J Med Virol* 66:229–234
- Béven L, Helluin O, Molle G, Duclohier H, Wróblewski H (1999) Correlation between anti-bacterial activity and pore sizes of two classes of voltage-dependent channel-forming peptides. *Biochim Biophys Acta* 1421:53–63
- Bevins CL, Zasloff M (1990) Peptides from frog skin. *Annu Rev Biochem* 59:395–414
- Bisht GS, Rawat DS, Kumar A, Kumar R, Pasha S (2007) Antimicrobial activity of rationally designed amino terminal modified peptides. *Bioorg Med Chem Lett* 17:4343–4346
- Blaylock LA, Ruibal R, Platt-Aloia K (1976) Skin structure and wiping behaviour of phyllomedusine frogs. *Copeia* 1976:283–295
- Boman HGJ (2003) Effect of peptide length on the interaction between consensus peptides and DOPC/DOPA bilayers. *Intern Med* 254:197–215
- Brand GD, Leite JRSA, Silva LP, Albuquerque S, Prates MV, Azevedo RB, Carregaro V, Silva JS, Sá VC, Brandao RA, Bloch C Jr (2002) Dermaseptins from *Phyllomedusa oreades* and *Phyllomedusa distincta*: anti-*Trypanosoma cruzi* activity without cytotoxicity to mammalian cells. *J Biol Chem* 277:49332–49340
- Brand GD, Krause FC, Silva LP, Leite JRSA, Melo JAT, Prates MV, Pesquero JB, Santos EL, Nakaie CR, Costa-Neto CM, Bloch C Jr (2006a) Bradykinin-related peptides from *Phyllomedusa hypochondrialis*. *Peptides* 27:2137–2146
- Brand GD, Leite JRSA, Mandel SMS, Mesquita DA, Silva LP, Prates MV, Barbosa EA, Vinecky F, Martins GR, Galasso JH, Kuckelhaus SAS, Sampaio RNR, Furtado JR, Andrade AC, Bloch C Jr (2006b) Novel dermaseptins from *Phyllomedusa hypochondrialis* (Amphibia). *Biochem Biophys Res Commun* 347:739–746
- Brocardo M, Erspamer V, Falconieri Erspamer G, Improta G, Linaii G, Melchiorri P, Montecucchi PC (1981) Pharmacological data on dermorphins. A new class of potent opioid peptides from amphibian skin. *Br J Pharmacol* 73:625–631
- Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol* 3:238–250
- Bruston F, Lacombe C, Zimmermann K, Piesse C, Nicolas P, El Amri C (2007) Structural malleability of plasticins: preorganized conformations in solution and relevance for antimicrobial activity. *Biopolymers* 86:42–56
- Calderon LA, Silva-Jardim I, Zuliani JP, Silva AA, Ciancaglini P, Silva LHP, Stábeli RG (2009a) Amazonian biodiversity: a view of drug development for leishmaniasis and malaria. *J Braz Chem Soc* 20:1011–1023
- Calderon LA, Messias MR, Serrano ROP, Zaqueo KD, Souza ED, Nienow SS, Cardozo-Filho JL, Diniz-Sousa R, Delaix-Zaqueo K, Stábeli RG (2009b) Amphibia, Anura, Hylidae, Phyllomedusinae, *Phyllomedusa azurea*: distribution extension and geographic distribution map. *Check List* 5(2):317–319
- Caramaschi U (2006) Redefinição do grupo de *Phyllomedusa hypochondrialis*, com redescoberta de *P. megacephala* (Miranda-Ribeiro, 1926), revalidação de *P. azurea* Cope, 1862 e descrição de uma nova espécie (Amphibia, Anura, Hylidae). *Arq Mus Nac* 64:159–179
- Castanho LM, De Luca IMS (2001) Moulting behavior in leaf-frogs of the genus *Phyllomedusa* (Anura: Hylidae). *Zool Anz* 240:3–6
- Castiglione-Morelli MA, Cristinziano P, Pepe A, Temussi PA (2005) Conformation–activity relationship of a novel peptide antibiotic:

- structural characterization of dermaseptin DS 01 in media that mimic the membrane environment. *Biopolymers* 80:688–696
- Cerdá-Reverter JM, Larhammar D (2000) Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. *Biochem Cell Biol* 78:371–392
- Chan DI, Prenner EJ, Vogel HJ (2006) Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. *Biochim Biophys Acta* 1758:1184–1202
- Charpentier S, Amiche M, Mester J, Vouille V, Le Caer JP, Nicolas P, Delfour A (1998) Structure, synthesis, and molecular cloning of dermaseptins B, a family of skin peptide antibiotics. *J Biol Chem* 273:14690–14697
- Chen T, Shaw C (2003) Cloning of the (Thr6)-phyllotoxin precursor from *Phyllomedusa sauvagei* skin confirms a non-consensus tyrosine O-sulfation motif. *Peptides* 24:1123–1130
- Chen T, Tang L, Shaw C (2003a) Identification of three novel *Phyllomedusa sauvagei* Dermaseptins (sVI-sVIII) by cloning from a skin secretion delivered cDNA library. *Regul Pept* 116:139–146
- Chen T, Farragher S, Bjorson AJ, Orr DF, Rao P, Shaw C (2003b) Granular gland transcriptomes in stimulated amphibian skin secretions. *Biochem J* 371:125–130
- Chen T, Walker B, Zhou M, Shaw C (2005a) Dermatoxin and Phylloxin from the waxy monkey frog, *Phyllomedusa sauvagei*: cloning of precursor cDNAs and structural characterization from lyophilized skin secretion. *Regul Pept* 129:103–108
- Chen TB, Gagliardo R, Walker B, Zhou M, Shaw C (2005b) Partial structure of the phylloxin gene from the giant monkey frog *Phyllomedusa bicolor*: parallel cloning of precursor cDNA and genomic DNA from lyophilized skin secretion. *Peptides* 26:2624–2628
- Chen TB, Zhou M, Gagliardo R, Walker B, Shaw C (2006) Elements of the granular gland peptidome and transcriptome persist in air-dried skin of the South American orange-legged leaf frog, *Phyllomedusa hypochondrialis*. *Peptides* 27:2129–2136
- Coloma LA (2009) Anfibios de Ecuador 2005–2009. 2.0 Museo de Zoología, Pontificia Universidad Católica del Ecuador. Quito, Ecuador. <http://www.puce.edu.ec/zoologia/vertebrados/amphibiawebec/anfibiosecuador/index.htm>. Accessed 10 Jan 2010
- Conceição K, Konno K, Richardson M, Antonazzi MM, Jared C, Daffre S, Camargo ACM, Pimenta DC (2006) Isolation and biochemical characterization of peptides presenting antimicrobial activity from the skin of *Phyllomedusa hypochondrialis*. *Peptides* 27:3092–3099
- Conceição K, Konno K, Melo RL, Antonazzi MM, Jared C, Sciani JM, Conceição IM, Prezoto BC, Camargo ACM, Pimenta DC (2007) Isolation and characterization of a novel bradykinin potentiating peptide (BPP) from the skin secretion. *Peptides* 28:515–523
- Conceição K, Bruni FM, Sciani JM, Konno K, Melo RL, Antonazzi MM, Jared C, Lopes-Ferreira M, Pimenta DC (2009) Identification of bradykinin-related peptides from *Phyllomedusa noredestina* skin secretion using electrospray ionization tandem mass spectrometry after a single-step liquid chromatography. *J Venom Anim Toxins Incl Trop Dis* 15:633–652
- Conlon JM, Chartrel N, Vaudry H (1992) Primary structure of frog PYY: implications for the molecular evolution of the pancreatic polypeptide family. *Peptides* 13:145–149
- Dagan A, Efron L, Gaidukov L, Mor A, Ginsburg H (2002) In vitro antiplasmodium effects of dermaseptins S4 derivatives. *Antimicrob Agents Chemother* 46:1059–1066
- Dalla SM, Cirioni O, Vitale RM, Renzone G, Coraiola M, Giacometti A, Potrich C, Baroni E, Guella G, Sanseverino M, De Luca S, Scalise G, Amodeo P, Scaloni A (2008) Structural features of distinct affecting peptide biological and biochemical properties. *Biochemistry* 47:7888–7899
- Daly JW, Caceres J, Moni RW, Gusovsky F, Moos M Jr, Seamon KB, Milton K, Myers CW (1992) Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. *Proc Natl Acad Sci USA* 89:10960–10963
- Dathe M, Wieprecht T (1999) Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. *Biochim Biophys Acta* 1462:71–87
- Delfino G (1991) Ultrastructural aspects of venom secretion in anuran cutaneous glands. In: Tu AT, Dekker M (eds) *Reptile venoms and toxins*. Handbook of natural toxins. Marcel Dekker Inc., New York, pp 777–802
- Delfino G, Brizzi R, Alvarez BB, Kracke-Berndorff R (1998) Serous cutaneous glands in *Phyllomedusa hypochondrialis* (Anura, Hylidae): secretory patterns during ontogenesis. *Tissue Cell* 30:30–40
- Edwards P (2007) Combinatorial approaches to combating multidrug resistance. *Drug Discov Today* 12:786–787
- El Amri C, Lacombe C, Zimmerman K, Ladram A, Amiche M, Nicolas P, Bruston F (2006) The plasticins: membrane adsorption, lipid disorders, and biological activity. *Biochemistry* 45:14285–14297
- Erspamer V (1992) The opioid peptides of the amphibian skin. *Int J Dev Neurosci* 10:3–30
- Erspamer V, Bertaccini G, Cei JM (1962) Occurrence of an eledoisin-like polypeptide (physalaemin) in skin extracts of *Physalaemus fuscumaculatus*. *Experientia* 18:562–563
- Erspamer V, Melchiorri P, Broccardo M, Erspamer GF, Falaschi P, Improta G, Negri L, Renda T (1981) The brain–gut–skin triangle: new peptides. *Peptides* 2:7–16
- Erspamer V, Melchiorri P, Falconieri Erspamer G, Montecucchi PC, De Castiglione R (1985) *Phyllomedusa* skin: a huge factory and store-house of a variety of active peptides. *Peptides* 6:7–12
- Erspamer V, Melchiorri P, Falconieri-Erspamer G, Negri L, Corsi R, Severini C, Barra D, Simmaco M, Kreil G (1989) Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. *Proc Natl Acad Sci USA* 86:5188–5192
- Faivovich J, Haddad CFB, Garcia PCA, Frost DR, Campbell JA, Wheller WC (2005) Systematic review of the frog family Hylidae, with special reference to Hylinae: phylogenetic analysis and taxonomic revision. *Bull Am Mus Nat Hist* 294:1–240
- Feder R, Dagan A, Mor A (2000) Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerisation on selective cytotoxicity. *J Biol Chem* 275:4230–4238
- Fleury Y, Dayem MA, Montagne JJ, Chaboisseau E, Le Caer JP, Nicolas P, Delfour A (1996) Covalent structure, synthesis, and structure-function studies of mesentericin Y105 (37), a defensive peptide from Gram-positive bacteria *Leuconostoc mesenteroides*. *J Biol Chem* 271:14421–14429
- Fleury Y, Vouille V, Beven L, Amiche M, Wroblewski H, Delfour A, Nicolas P (1998) Synthesis, antimicrobial activity and gene structure of a novel member of the dermaseptin B family. *Biochim Biophys Acta* 1396:228–236
- Frost DR (2009) Amphibian species of the world: an online reference, Version 5.3. American Museum of Natural History, New York, USA. <http://research.amnh.org/herpetology/amphibia/index.php>. Accessed 2 Jan 2010
- Gaidukov L, Fish A, Mor A (2003) Analysis of membrane-binding properties of dermaseptin analogues: relationships between binding and cytotoxicity. *Biochemistry* 42:12866–12874

- Ghosh JK, Shaool D, Guillaud P, Ciceron L, Mazier D, Kustanovich I, Shai Y, Mor A (1997) Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic *Plasmodium falciparum* and the underlying molecular basis. *J Biol Chem* 272:31609–31616
- Giacometti A, Cirioni O, Ghiselli R, Orlando F, Silvestri C, Renzone G, Testa I, Mocchegiani F, Della Vittoria A, Saba V, Scaloni A, Scalise G (2006) Distinctin improves the efficacies of glycopeptides and betalactams against staphylococcal biofilm in an experimental model of central venous catheter infection. *J Biomed Mater Res A* 81:233–239
- Gomes A, Giri B, Saha A, Mishra R, Dasguta SC, Debnath A, Gomes A (2007) Bioactive molecules from amphibian skin: their biological activities with reference to therapeutic potential for possible drug development. *Indian J Exp Biol* 45:579–593
- Gozzini L, Montecucchi PC, Erspamer V, Melchiorri P (1985) Tryptophyllins from extracts of *Phyllomedusa rohdei* skin: new tetra-, penta- and hepta-peptides. *Int J Pept Protein Res* 25:323–329
- Gregory SM, Cavanaugh A, Journigan V, Pokorny A, Almeida PFF (2008) A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide cecropin A. *Biophys J* 94:1667–1680
- Hancock REW (1997) Peptide antibiotics. *Lancet* 349:418–422
- Hancock REW, Lehrer R (1998) Cationic peptides: a new source of antibiotics. *Trends Biotechnol* 16:82–88
- Harzer U, Bechinger B (2000) The alignment of lysine-anchored membrane peptides under conditions of hydrophobic mismatch: a CD, 15N and 31P solid-state NMR spectroscopy investigation. *Biochemistry* 39:13106–13114
- Haug BE, Stensena W, Svendsen JS (2007) Application of the Suzuki–Miyaura cross-coupling to increase antimicrobial potency generates promising novel antibacterials. *Bioorg Med Chem Lett* 17:2361–2364
- Hawrami A, Howe RA, Walsh TR, Dempsey CE (2008) Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. *J Biol Chem* 283:18636–18645
- Hernandez C, Mor A, Dagger F, Nicolas P, Hernandez A, Benedetti EL, Dunia I (1992) Functional and structural damage in *Leishmania mexicana* exposed to the cationic peptide dermaseptin. *Eur J Cell Biol* 59:414–424
- Hilpert K, Elliott MR, Volkmer-Engert R, Henklein P, Donini O, Zhou Q, Winkler DF, Hancock RE (2006) Sequence requirements and an optimization strategy for short antimicrobial peptides. *Chem Biol* 13:1101–1107
- Huang HW, Chen FY, Lee MT (2004) Molecular mechanism of peptide-induced pores in membranes. *Phys Rev Lett* 92:198304–198307
- Huguenin F, Zucolotto V, Carvalho AJF, Gonzalez ER, Oliveira ON (2005) Layer-by-layer hybrid films incorporating WO₃, TiO₂ and chitosan. *Chem Mater* 17:6739–6745
- Hwang PM, Vogel HJ (1998) Structure–function relationships of antimicrobial peptides. *Biochem Cell Biol* 76:235–246
- Jones AJS, Epand RM, Lin KF, Walton D, Vail WJ (1978) Size and shape of the model lipoprotein complex formed between glucagon and dimyristolglycerophosphocholine. *Biochemistry* 17:2301–2307
- Koczulla AR, Bals R (2003) Antimicrobial peptides—current status and therapeutic potential. *Drugs* 63:389–406
- Kohri K, Nata K, Yonekura H, Nagai A, Konno K, Okamoto H (1993) Cloning and structural determination of human peptide YY cDNA and gene. *Biochim Biophys Acta* 1173:345–349
- Krugliak M, Feder R, Zolotarev VY, Gaidukov L, Dagan A, Ginsburg H, Mor A (2000) Antimalarial activities of dermaseptin S4 derivatives. *Antimicrob Agents Chemother* 44:2442–2451
- Kückelhaus SAS, Leite JRSA, Neves MP, Frota KS, Abdala LF, Muniz-Junqueira MI, Bloch C Jr, Tosta CE (2006) Toxicity evaluation to mice of phylloseptin-1, an antimicrobial peptide from the skin secretion of *Phyllomedusa hypochondrialis* (Amphibia). *Int J Pept Res Ther* 13:423–429
- Kückelhaus SAS, Leite JRSA, Muniz-Junqueira MI, Sampaio RN, Bloch C Jr, Tosta CE (2009) Antiplasmodial and antileishmanial activities of phylloseptin-1, an antimicrobial peptide from the skin secretion of *Phyllomedusa azurea* (Amphibia). *Exp Parasitol* 123:11–16
- Kustanovich I, Shalev DE, Mikhlin M, Gaidukov L, Mor A (2002) Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. *J Biol Chem* 277:16941–16951
- Kwong PD, McDonald NQ, Singler PB, Hendrickson WA (1995) Structure of beta 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. *Structure* 3:1109–1119
- Lacombe C, Cifuentes-Diaz C, Dunia I, Auber-Thomay M, Nicolas P, Amiche M (2000) Peptide secretion in the cutaneous gland of South American tree frog *Phyllomedusa bicolor*: an ultrastructural study. *Eur J Cell Biol* 79:631–641
- Lazarus LH, Attila M (1993) The toad, ugly and venomous, wears yet a precious jewel in his skin. *Progr Neurobiol* 41:473–507
- Lazarus LH, Bryant SD, Cooper PS, Salvadori S (1999) What peptides these deltorphins be. *Progr Neurobiol* 57:377–420
- Leite JRSA, Silva LP, Rodrigues MI, Prates MV, Brand GD, Lacava BM, Azevedo RB, Bocca AL, Albuquerque S, Bloch C Jr (2005) Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the *Phyllomedusa* genus. *Peptides* 26:565–573
- Leite JRSA, Brand GD, Silva LP, Kückelhaus SAS, Bento WRC, Araújo ALT, Martins GR, Lazzari AM, Carlos Bloch Jr C (2008) Dermaseptins from *Phyllomedusa oreades* and *Phyllomedusa distincta*: secondary structure, antimicrobial activity, and mammalian cell toxicity. *Comp Biochem Physiol A Mol Integr Physiol* 151:336–343
- Lequin O, Bruston F, Convert O, Chassaing G, Nicolas P (2003) Helical structure of dermaseptin B2 in a membrane-mimetic environment. *Biochemistry* 42:10311–10323
- Lequin O, Ladram A, Chabbert L, Bruston F, Convert O, Vanhoye D, Chassaing G, Nicolas P, Amiche M (2006) Dermaseptin S9, an α -helical antimicrobial peptide with a hydrophobic core and cationic termini. *Biochemistry* 45:468–480
- Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis* 6:589–601
- Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H (2005) The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. *Virology* 334:264–275
- Mandel SMS (2008) Prospecção de peptídeos antimicrobianos da secreção cutânea de anfíbios do gênero *Phyllomedusa*. Dissertation. Universidade de Brasília
- Marenah L, McClean S, Flatt PR, Orr DF, Shaw C, Abdel-Wahab YH (2004) Novel insulin-releasing peptides in the skin of *Phyllomedusa trinitatis* frog include 28 amino acid peptide from dermaseptin BIV precursor. *Pancreas* 29:110–115
- Marr AK, Gooderham WJ, Hancock REW (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. *Curr Opin Pharmacol* 6:468–472
- Matsuzaki K (1998) Magainins as paradigm for the mode of action of pore forming polypeptides. *Biochim Biophys Acta* 1376:391–400
- Matsuzaki K (2009) Control of cell selectivity of antimicrobial peptides. *Biochim Biophys Acta* 1788:1687–1692
- Mignogna G, Severini C, Simmaco M, Negri L, Falconieri Erspamer G, Kreil G, Barra D (1992) Identification and characterization of two dermorphins from skin extracts of the Amazonian frog *Phyllomedusa bicolor*. *FEBS Lett* 302:151–154

- Moellering RC Jr (2003) New approaches to developing antimicrobials for resistant bacteria. *J Infect Chemother* 9:8–11
- Montecucchi PC, Henschen A, Erspamer V (1979) Structure of sauvagine, a vasoactive peptide from the skin of a frog. *Hoppe-Seylers Z Physiol Chem* 360:1178
- Montecucchi PC, Anastasi A, De Castiglione R, Erspamer V (1980) Isolation and amino acid composition of sauvagine, an active polypeptide from methanol extracts of the skin of the South American frog *Phyllomedusa sauvagei*. *Int J Pept Protein Res* 16:191–199
- Montecucchi PC, De Castiglione R, Piani S, Gozzini L, Erspamer V (1981a) Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of *Phyllomedusa sauvagei*. *Int J Pept Protein Res* 17:275–283
- Montecucchi PC, De Castiglione R, Erspamer V (1981b) Identification of dermorphin and Hyp δ -dermorphin in skin extracts of the Brazilian frog *Phyllomedusa rhodei*. *Int J Pept Protein Res* 17:316–321
- Montecucchi PC, Gozzini L, Erspamer V (1986) Primary structure determination of a tryptophan-containing tridecapeptide from *Phyllomedusa rohdei*. *Int J Pept Protein Res* 27:175–182
- Mor A, Nicolas P (1994a) Isolation and structure of novel defensive peptides from frog skin. *Eur J Biochem* 219:145–154
- Mor A, Nicolas P (1994b) The NH₂-terminal α -helical domain 1–18 of dermaseptin is responsible for antimicrobial activity. *J Biol Chem* 269:1934–1939
- Mor A, Delfour A, Nicolas P (1991a) Identification of a D-alanine-containing polypeptide precursor for the peptide opioid, dermorphin. *J Biol Chem* 266:6264–6270
- Mor A, Nguyen VH, Delfour A, Migliore D, Nicolas P (1991b) Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. *Biochemistry* 30:8824–8830
- Mor A, Amiche M, Nicolas P (1994a) Structure, synthesis, and activity of dermaseptin B. A novel vertebrate defensive peptide from frog skin: relationship with adenoregulin. *Biochemistry* 33:6642–6650
- Mor A, Chartrel N, Vaudry H, Nicolas P (1994b) Skin peptide tyrosine-tyrosine, a member of the pancreatic polypeptide family: Isolation, structure, synthesis, and endocrine activity. *Proc Natl Acad Sci USA* 91:10295–10299
- Mor A, Hani K, Nicolas P (1994c) The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. *J Biol Chem* 269:31635–31641
- Mundim NCCR (2008) Prospecção de bradicininas de anfíbios do gênero *Phyllomedusa*. Dissertation. Universidade de Brasília
- Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A (2002) Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. *Antimicrob Agents Chemother* 46:689–694
- Nicolas P, El Amri C (2009) The dermaseptin superfamily: A gene-based combinatorial library of antimicrobial peptides. *Biochim Biophys Acta* 1788:1537–1550
- Nicolas P, Vanhoye D, Amiche M (2003) Molecular strategies in biological evolution of antimicrobial peptides. *Peptides* 24:1669–1680
- Papo N, Shai Y (2003) Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? *Peptides* 24:1693–1703
- Perron GG, Zasloff M, Bell G (2006) Experimental evolution of resistance to an antimicrobial peptide. *Proc Roy Soc Lond B* 273:251–256
- Peschel A, Sahl HG (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nat Rev Microbiol* 4:529–536
- Pierre TP, Seon AA, Amiche M, Nicolas P (2000) Phylloxin, a novel peptide antibiotic of the dermaseptin family of antimicrobial/opioid peptide precursors. *Eur J Biochem* 267:370–378
- Poulter L, Terry AS, Williams DH, Giovannini MG, Moore CH, Gibson BW (1988) Levitide, a new hormone-like peptide from the skin of *Xenopus laevis*. Peptide and peptide precursor cDNA sequence. *J Biol Chem* 263:3279–3283
- Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y (1992) Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. *Biochemistry* 31:12416–12423
- Pukkila-Worley R, Mylonakis E (2008) Epidemiology and management of cryptococcal meningitis: developments and challenges. *Expert Opin Pharmacother* 9:551–560
- Resende JM, Moraes CM, Prates MV, Cesar A, Almeida FCL, Mundim NCCR, Valente AP, Bemquerer MP, Piló-Veloso DA, Bechinger B (2008) Solution NMR structures of the antimicrobial peptides phylloseptin-1, -2, and -3 and biological activity: the role of charges and hydrogen bonding interactions in stabilizing helix conformations. *Peptides* 29:1633–1644
- Richter K, Egger R, Kreil G (1987) D-Alanine in the frog skin peptide dermorphin is derived from L-alanine in the precursor. *Science* 238:200–202
- Richter K, Egger R, Negri L, Corsi R, Severini C, Kreil G (1990) cDNAs encoding [D-Ala₂]deltorphin precursors from skin of *Phyllomedusa bicolor* also contain genetic information for three dermorphin-related opioid peptides. *Proc Natl Acad Sci USA* 87:4836–4839
- Rivas L, Luque-Ortega JR, Andreu D (2009) Amphibian antimicrobial peptides and protozoa: lessons from parasites. *Biochim Biophys Acta* 1788:1570–1581
- Rotem S, Mor A (2009) Antimicrobial peptide mimics for improved therapeutic properties. *Biochim Biophys Acta* 1788:1582–1592
- Rydlo T, Sotem S, Mor A (2006) Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions. *Antimicrob Agents Chemother* 50:490–507
- SBH (2009) Lista de espécies de anfíbios do Brasil. Sociedade Brasileira de Herpetologia (SBH). <http://www.sberpetologia.org.br/checklist/anfibios.htm>. Accessed 12 Jan 2010
- Sengupta D, Leontiadou H, Mark AE, Marrink SJ (2008) Toroidal pores formed by antimicrobial peptides show significant disorder. *Biochim Biophys Acta* 1778:2308–2317
- Seon AA, Pierre TN, Redeker V, Lacombe C, Delfour A, Nicolas P, Amiche M (2000) Isolation, structure, synthesis, and activity of a new member of the calcitonin gene-related peptide family from frog skin and molecular cloning of its precursor. *J Biol Chem* 275:5934–5940
- Serra MD, Cirioni O, Vitale RM, Renzone G, Coraiola M, Giacometti A, Potrich C, Baroni E, Guella G, Sanseverino M, De Luca S, Scalise G, Amodeo P, Scaloni A (2008) Structural features of distinct affecting peptide biological and biochemical properties. *Biochemistry* 47:7888–7899
- Shai Y (1995) Molecular recognition between membrane-spanning polypeptides. *Trends Biochem Sci* 20:460–464
- Shai Y (2002) Mode of action of membrane active antimicrobial peptides. *Biopolymers* 66:236–248
- Shalev DE, Mor A, Kustanovich I (2002) Structural consequences of carboxyamidation of dermaseptin S3. *Biochemistry* 41:7312–7317
- Shaw C (2009) Advancing drug discovery with reptile and amphibian venom peptides, venom-based medicines. *Biochem Soc* 31:34–37
- Shin Y, Moni RW, Lueders JE, Daly JW (1994) Effects of the amphiphilic peptides mastoparan and adenoregulin on receptor binding, G proteins, phosphoinositide breakdown, cyclic AMP generation, and calcium influx. *Cell Mol Neurobiol* 14:133–157
- Shukla A, Fleming KE, Chuang HF, Chau TM, Loose CR, Stephanopoulos GN, Hammond PT (2009) Controlling the release of peptide antimicrobial agents from surfaces. *Biomaterials* 31(8):2348–2357

- Silva LR, Batista CVF, Prates MV, Gordo M, Bloch C Jr (2000) A new antimicrobial peptide homologous to the dermaseptins isolated from *Phyllomedusa tarsius*. *Toxicon* 38:554–555
- Silva LP, Leite JR, Brand GD, Regis WB, Tedesco AC, Azevedo RB, Freitas SM, Bloch C Jr (2008) Dermaseptins from *Phyllomedusa oreades* and *Phyllomedusa distincta*: liposomes fusion and/or lysis investigated by fluorescence and atomic force microscopy. *Comp Biochem Physiol A Mol Integr Physiol* 151:329–335
- Siqueira JR Jr, Gasparotto LHS, Crespilho FN, Carvalho AJF, Zucolotto V, Oliveira ON Jr (2006) Physicochemical properties and sensing ability of metallophthalocyanines/chitosan nanocomposites. *J Phys Chem B* 110:22690–22694
- Strahilevitz J, Mor A, Nicolas P, Shai Y (1994) Spectrum of antimicrobial activity and assembly of dermaseptin B and its precursor form in phospholipid membranes. *Biochemistry* 33:10951–10960
- Thompson AH (2006) A genomic/proteomic approach to isolating and identifying bioactive peptides from the skin secretions of *Phyllomedusa hypochondrialis azurea*. Thesis. University of Ulster Coleraine
- Thompson AH, Bjourson AJ, Shaw C, McClean S (2006) Bradykinin-related peptides from *Phyllomedusa hypochondrialis azurea*: Mass spectrometric structural characterisation and cloning of precursor cDNAs. *Rapid Commun Mass Spectr* 20:3780–3788
- Thompson AH, Bjourson AJ, Orr DF, Shaw C, McClean S (2007a) A combined mass spectrometric and cDNA sequencing approach to the isolation and characterization of novel antimicrobial peptides from the skin secretions of *Phyllomedusa hypochondrialis azurea*. *Peptides* 28:1331–1343
- Thompson AH, Bjourson AJ, Orr DF, Shaw C, McClean S (2007b) Amphibian skin secretomics: application of parallel quadrupole time-of-flight mass spectrometry and peptide precursor cDNA cloning to rapidly characterize the skin secretory peptidome of *Phyllomedusa hypochondrialis azurea*: discovery of a novel peptide family, the hyposins. *J Proteome Res* 6:3604–3613
- Toledo RC, Jared C (1993) Cutaneous adaptations to water balance in amphibians. *Comp Biochem Physiol* 105:593–608
- Toledo RC, Jared C (1995) Cutaneous granular glands and amphibian venoms. *Comp Biochem Physiol* 111:1–29
- UniProt (2009) The UniProt Consortium. The Universal Protein Resource (UniProt). *Nucl Acids Res* 37:D169–D174
- Vaara M (2009) New approaches in peptide antibiotics. *Curr Opin Pharmacol* 9(5):571–576
- van't HW, Veerman EC, Helmerhorst EJ, Amerongen AV (2001) Antimicrobial peptides: properties and applicability. *Biol Chem* 382:597–619
- Vanhoye D, Bruston F, Nicolas P, Amiche M (2003) Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. *Eur J Biochem* 270:2068–2081
- Vanhoye D, Bruston F, El Amri S, Ladram A, Amiche M, Nicolas P (2004) Membrane Association, electrostatic sequestration, and cytotoxicity of gly-leu-rich peptide orthologs with differing functions. *Biochemistry* 43:8391–8409
- Verly RM, Rodrigues MA, Daghestanli KR, Denadai AM, Cuccovia IM, Bloch C Jr, Frézard F, Santoro MM, Piló-Veloso D, Bemquerer MP (2008) Effect of cholesterol on the interaction of the amphibian antimicrobial peptide DD K with liposomes. *Peptides* 29:15–24
- Verly RM, Moraes CM, Resende JM, Aisenbrey C, Bemquerer MP, Piló-Veloso D, Valente AP, Almeida FCL, Beching B (2009) Structure and membrane interactions of the antibiotic peptide dermadistinctin K by multidimensional solution and oriented ¹⁵N and ³¹P solid-state NMR spectroscopy. *Biophys J* 96:2194–2203
- Vouille V, Amiche M, Nicolas P (1997) Structure of genes for dermaseptins B, antimicrobial peptides from frog skin. *FEBS Lett* 414:27–31
- Vouldoukis I, Shai Y, Nicolas P, Mor A (1996) Broad spectrum antibiotic activity of the skin-PYY. *FEBS Lett* 380:237–240
- Wang L, Zhou M, Zhou Z, Chen T, Walker B, Shaw C (2009) Sauvatide—a novel amidated myotropic decapeptide from the skin secretion of the waxy monkey frog, *Phyllomedusa sauvagei*. *Bioch Biophys Res Commun* 383:240–244
- Wang H, Xu K, Liu L, Tan JPK, Chen Y, Li Y, Fan W, Wei Z, Sheng J, Yang YY, Li L (2010) The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against *Cryptococcus neoformans* for the treatment of meningitis. *Biomaterials* 31(10):2874–2881
- Wieprecht T, Dathe M, Krause E, Beyermann M, Maloy WL, MacDonald DL, Bienert M (1997) Modulation of membrane activity of amphipathic, antibacterial peptides by slight modifications of the hydrophobic moment. *FEBS Lett* 417:135–140
- Yasuhara T, Nakajima T, Falconieri Erspamer G, Erspamer V (1981) New tachykinins Glu2, Pro5-kassinin (Hylambates-kassinin) and hylambatin in the skin of the African rhacophorid frog *Hylambates maculates*. *Biomed Res* 2:613–617
- Yasuhara T, Nakajima T, Nokihara K, Yanaihara C, Yanaihara N, Erspamer V, Falconieri Erspamer G (1983) Two new, frog skin peptides, phyllolitorins, of the bombesin-ranatsensin family. *Biomed Res* 4:407–412
- Yeaman MR, Yount NY (2003) Mechanisms of antimicrobial peptide action and resistance. *Pharmacol Rev* 55:27–55
- Zairi A, Tangy F, Saadi S, Hani K (2008) In vitro activity of dermaseptin S4 derivatives against genital infections pathogens. *Regul Toxicol Pharmacol* 50:353–358
- Zairi A, Tangy F, Bouassida K, Hani K (2009) Dermaseptins and magainins: antimicrobial peptides from frogs' skin—new sources for a promising spermicides microbicides. *J Biomed Biotechnol* 2009:1–8
- Zampa MF, de Brito AC, Kitagawa IL, Constantino CJ, Oliveira ON Jr, da Cunha HN, Zucolotto V, dos Santos JR Jr, Eiras C (2007) Natural gum-assisted phthalocyanine immobilization in electroactive nanocomposites: physicochemical characterization and sensing applications. *Biomacromolecules* 8:3408–3413
- Zampa MF, Araújo IMS, Costa V, Costa CHN, Santos JR Jr, Zucolotto V, Eiras C, Leite JRSA (2009) Leishmanicidal Activity and Immobilization of dermaseptin 01 antimicrobial peptides in ultrathin films for nanomedicine applications. *Nanomedicine* 5:352–358
- Zasloff M (2002) Antimicrobial peptides of multicellular organisms. *Nature* 415:389–395
- Zhang L, Parente J, Harris SM, Woods DE, Hancock REW, Falla TJ (2005) Antimicrobial peptide therapeutics for cystic fibrosis. *Antimicrob Agents Chemother* 49:2921–2927
- Zucolotto V, Pinto AP, Tumolo T, Moraes ML, Baptista MS, Riul A Jr, Araújo AP, Oliveira ON Jr (2006) Catechol biosensing using a nanostructured layer-by-layer film containing Cl-catechol 1, 2 dioxygenase. *Biosens Bioelectron* 21:1320–1326
- Zucolotto V, Daghestanli KRP, Hayasaka CO, Riul A Jr, Ciancaglini P, Oliveira ON Jr (2007) Using capacitance measurements as the detection method in antigen-containing layer-by-layer films for biosensing. *Anal Chem* 79:2163–2167